Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ror gamma (t))

ABSTRACT

Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma RORγt are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/537,678, filed Jun. 19, 2017, which is the National Stage of PCT/EP2015/080689, filed Dec. 18, 2015, published on Jun. 23, 2016 as WO 2016/097391 A1, which claims priority to French Application No. 1463035, filed Dec. 19, 2014 and to French Application No. 1556341, filed Jul. 3, 2015. The contents of these applications are herein incorporated by reference in their entirety.

The present invention relates to particular bicyclic sulfonamide derivatives, to the pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof, and also to the use thereof as inverse agonist of the retinoid-related orphan receptor gamma RORγt.

The invention also relates to a pharmaceutical composition comprising such compounds and also to the use thereof for the topical and/or oral treatment of inflammatory diseases mediated by the RORγt receptors, especially acne, atopic dermatitis and/or psoriasis.

The nuclear receptors form a large family (known as a superfamily) of transcription factors which correspond to proteins that are capable of being activated by a ligand, of binding to specific DNA sequences and of regulating the transcription of target genes. Thus, these receptors are involved in the regulation of a wide variety of biological functions, including growth, development, reproduction, differentiation and metabolism in a multitude of living organisms.

The first members of this superfamily that were identified and described in the scientific literature are the nuclear receptors of steroid hormones such as the glucocorticoid receptors and the estrogen receptors. This superfamily also comprises among its members many receptors for which no ligand has been identified. These nuclear receptors are known as “orphan receptors”.

Retinoid-related orphan receptors thus constitute a subfamily of nuclear receptors. This subfamily is composed of three members each having an intrinsic expression profile: ROR alpha (known as RORα), ROR beta (known as ROM and ROR gamma (known as RORγ). Two isoforms of the orphan receptors RORγ have already been identified, namely RORγ1, which is expressed in a variety of tissues such as the thymus, the kidneys, muscles and the liver, and RORγ2 (also known as RORγt), which is expressed exclusively in the cells of the immune system.

In particular, the receptor RORγt plays an important regulating role in cell differentiation of the Th17 lymphocytes which correspond to helper T lymphocytes whose function is to ensure the defence of the body against a large number of extracellular pathogens such as bacteria and fungal infections.

However, it has been demonstrated that the Th17 lymphocytes are also involved in a wide variety of inflammatory disorders, such as acne, and of autoimmune diseases such as psoriasis, rheumatoid arthritis or multiple sclerosis (Peck A, Mellins E D. Precarious balance; Th17 cells in host defense. Infect. Immun. 2010 January; 78(1): 32-8; Suarez-Farinas: J. Allergy Clin. Immunol. 2014; J. Invest. Dermatol. 2008, 128(11), 2625).

Specifically, the Th17 lymphocytes produce numerous cytokines which have distinct profiles, such as interleukin-17A (IL-17A), interleukin-17F (IL-17F), interleukin-26 (IL-26), interleukin-21 (IL-21), interleukin-22 (IL-22) and TNFα, the development, survival and proliferation of which depend on interleukin-23 (IL-23). These cytokines are capable of activating different types of effector cells, such as keratinocytes, thus leading to their hyperproliferation and to the additional production of pro-inflammatory cytokines, chemokines and antimicrobial peptides, which in turn recruit and activate other immune system cells in the inflamed skin, which may lead to amplification of the immune response.

Thus, activation of the Th17 lymphocytes is responsible for the recruitment of cytokines, especially of interleukin-17 (IL17), and of other types of pro-inflammatory cells, which will lead to the mediation of inflammatory disorders such as acne and/or of autoimmune diseases such as psoriasis.

Experiments conducted on mice show that a decrease in the level of expression of the RORγt receptor leads to a decrease in the activity of the Th17 lymphocytes, which consequently makes it possible to greatly reduce the expression of interleukin-17 (IL-17) (Ivanov I I, McKenzie B S, Zhou L, Tadokoro C E, Lepelley A, Lafaille J J, Cua D J, Littman D R: Cell 2006, 126, 1121-1133) and to efficiently treat inflammatory disorders and autoimmune diseases mediated by these cytokines, especially those for which high levels of interleukin-17 (IL-17) are detected.

To this end, patent application WO 2013/160 418 describes sulfonamide compounds used as inverse agonists of the RORγt receptor in order to be able to treat inflammatory disorders and autoimmune diseases. Similarly, other compounds have also been developed as inverse agonists of the RORγt receptor, such as those described in patent applications WO 2014/090 712, WO 2014/008 214, WO 2013/169 588, WO 2013/160 419, WO 2013/1 002 027, WO 2013/092 939, WO 2013/092 941, WO 2013/085 890 and WO 2012/100 732.

There is thus a real need to develop novel compounds as inverse agonists of the RORγt receptor in order to be able to efficiently treat diseases mediated by such a receptor, especially inflammatory disorders such as acne, and/or autoimmune diseases such as psoriasis or atopic dermatitis.

This aim is achieved by means of the use of particular bicyclic sulfonamide derivatives as described below, which make it possible to modulate the activity of the RORγt receptor and consequently to efficiently treat inflammatory disorders and autoimmune diseases of certain pathologies.

One subject of the present invention is thus especially one or more compounds of formula (Ia), the pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof:

in which formula (I):

-   -   L represents a single bond or a methylene group CH₂,     -   X represents a cyclic radical chosen from the radicals X₁ and X₂         below:

-   -   one or two of the elements Y¹, Y², Y³, Y⁴ and Y⁵ represent(s) a         nitrogen atom and the other elements correspond to a group —CR²,         or each of the elements Y¹, Y², Y³, Y⁴ and Y⁵ corresponds to a         group —CR²,     -   one or two of the elements Q¹, Q² and Q³ represent(s) a nitrogen         atom and the other element(s) correspond(s) to a group —CR^(2a),         or each of the elements Q¹, Q² and Q³ corresponds to a group         —CR^(2a),     -   R¹ represents a linear or branched C₃-C₅ alkyl radical,         optionally substituted with a hydroxyl group and/or a halogen         atom, a C₃-C₅ cycloalkyl radical, a linear or branched C₂-C₅         alkenyl radical, a (C₁)alkyl(C₃-C₅)cycloalkyl radical, a C₄-C₅         heterocycloalkyl radical, a (C₁)alkyl(C₄-C₆)heterocycloalkyl         radical,     -   R² represents a hydrogen atom or a halogen atom, a linear or         branched C₁-C₅ alkyl radical, a linear or branched C₂-C₄ alkenyl         radical, a C₁-C₄ alkoxy radical, a cyano group —CN, a radical         —C(═O)R′² with R′² denoting a C₁-C₃ alkoxy radical, a —CF₃         radical; said alkyl, alkenyl and alkoxy radicals possibly being         substituted with one or more halogen atoms,     -   R^(2a) represents a hydrogen atom or a halogen atom, a linear or         branched C₁-C₅ alkyl radical, a linear or branched C₂-C₄ alkenyl         radical, a C₁-C₄ alkoxy radical, a-CN group, a hydroxyl group         —OH, a group —CH(R^(3a))OH, a carboxylic group —COOH, a         carbamoyl group —CONR^(2c)R^(2d), an amido group         —NR^(2c)COR^(2d), a group —SO₂R^(2c), a group —SOR^(2c), a group         —S(═O)(═NH—R^(2c)), said alkyl, alkenyl and alkoxy radicals         possibly being substituted with one or more halogen atoms,     -   R^(2c) and R^(2d), which may be identical or different,         represent a hydrogen atom or a linear or branched C₁-C₅ alkyl         radical;     -   R^(3a) represents a hydrogen atom or a linear or branched C₁-C₅         alkyl radical,     -   R³ represents a hydrogen atom, a halogen atom, a group         (CHR⁶)_(n)—(Z)O—(CHR^(′6))_(p)—R⁷, a group CH═R⁷ or a group         —C═CH—R⁷,     -   n, o and p, which may be identical or different, represent zero         or a natural integer ranging from 1 to 3,     -   —Z represents a divalent group chosen from a methylene group         —CH₂—, an amino group —NH— and an oxygen atom —O—,     -   R⁶ and R^(′6), which may be identical or different, represent a         hydrogen atom, a methyl group —CH₃, a group —OH, a C₁         hydroxyalkyl group, a carboxylic function —COOH,     -   R⁷ represents:     -   a hydrogen atom or a halogen atom,     -   a group COOR^(′7) with R^(′7) denoting (C₁)alkyl(C₆)heterocycle,     -   a non-cationic heterocyclic radical optionally substituted with         one or more halogen atoms, one or more linear or branched C₁-C₃         alkyl groups, one or more —OH groups, one or more carbonyl         functions, one or more linear or branched C₁-C₄ hydroxyalkyl         groups, one or more amino groups, one or more groups         —C(═O)R^(7a), one or more groups S(═O)₂R^(7a); R^(7a)         representing a linear or branched C₁-C₃ alkyl radical, a linear         or branched C₁-C₃ alkoxy radical, or an amino radical         N(R^(8a))(R^(8b)),     -   a non-cationic C₃-C₆ cycloalkyl radical optionally substituted         with one or more C₁ alkyl radicals, one or more halogen atoms, a         cyano group —CN or one or more groups —COR⁹; R⁹ denoting a         linear or branched C₁-C₃ alkoxy radical, or a hydroxyl group,     -   an aromatic or heteroaromatic, non-cationic radical optionally         substituted with one or more halogen atoms, one or more linear         or branched C₁-C₃ alkyl groups optionally substituted with one         or more halogen atoms, one or more C₁-C₃ alkoxy groups, one or         more amino groups —NR¹¹R¹², one or more groups —COR¹¹, one or         more groups —COOR¹¹, one or more amido groups —CONR¹¹R¹², one or         more groups —SOR¹¹, one or more groups —SO₂R¹¹, one or more         groups —NHCOR¹¹, one or more groups —NHCOOR¹¹, one or more         groups —SO₂NR¹¹R¹² or one or more —CN groups; R¹¹ and R¹², which         may be identical or different, representing a hydrogen atom, a         hydroxyl radical —OH, a linear or branched C₁-C₃ alkyl radical         optionally substituted with one or more halogen atoms;     -   when R³ represents a group —CH═R⁷ or a group —C═CH—R⁷, then R⁷         does not represent a hydrogen atom, a halogen atom or a group         COOR^(′7),     -   R⁵ represents a hydrogen atom or a halogen atom, a linear or         branched C₁-C₃ alkyl radical optionally substituted with one or         more halogen atoms; an amino radical —NH₂, a C₄-C₅ heterocyclic         radical, an OCH₂—(C₄-C₅)heterocyclic radical, a radical         CH₂R^(′7a) with R^(′7a) denoting a C₁ alkoxy radical, a hydroxyl         group-OH, a —CH₂COOH group, a group —CH(R^(5b))OH, an amino         group —NH₂, a carboxylic group —COOH, a —CN group, a thioxo         function,     -   R^(5b) represents a hydrogen atom, a linear or branched C₁-C₃         alkyl radical optionally substituted with one or more carboxylic         functions; a cyclopropyl radical,     -   R^(8a) and R^(8b), which may be identical or different, denote a         hydrogen atom, a linear or branched C₁-C₃ alkyl radical or a         cyclopropyl radical.

The compound(s) according to the invention thus correspond to bicyclic sulfonamide derivatives, and thus to one or more sulfonamide compounds bearing in their structure at least two rings that are fused to each other.

In other words, X is a cyclic radical fused to the aromatic nucleus, comprising the elements Q¹, Q² and Q³ as defined above.

In accordance with the definition of formula (I), the endocyclic bond between the cyclic radical X₁ or X₂, as represented above, and the aromatic nucleus comprising the elements Q₁ to Q₃ is a double bond. Thus, the double bond is common between the cyclic radical X₁ or X₂ and the aromatic nucleus comprising the elements Q₁ to Q₃.

The compounds according to the invention make it possible to modulate, i.e. to inhibit, the activity of the RORγt receptor.

A subject of the present invention is also the compound(s) as defined previously, as medicament and cosmetic.

Another subject of the invention relates to the compound(s) as defined previously for their use in the treatment of diseases mediated by the RORγt receptor, especially inflammatory disorders and/or autoimmune diseases mediated by the RORγt receptor.

Moreover, the invention also relates to a pharmaceutical composition comprising, in a pharmaceutically acceptable medium, one or more compounds of formula (I) as defined previously, pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof.

The present invention also relates to the pharmaceutical composition as described previously, for its use in the treatment of diseases mediated by the RORγt receptor, especially inflammatory disorders and/or autoimmune diseases.

Finally, the invention relates to a method for treating diseases mediated by the RORγt receptor, comprising the administration, especially topically or orally, of a therapeutically effective amount of one or more compounds as defined above to a patient.

Other subjects, characteristics, aspects and advantages of the invention will emerge even more clearly on reading the description and the examples that follow.

According to one embodiment, in formula (I):

-   -   R³ represents a hydrogen atom, a group         (CHR⁶)_(n)—(Z)_(o)—(CHR¹⁶)_(p)—R⁷, a group CH═R⁷ or a group         —C═CH—R⁷, and     -   R⁵ represents a hydrogen atom or a halogen atom, a linear or         branched C₁-C₃ alkyl radical optionally substituted with one or         more halogen atoms; an amino radical —NH₂, a radical CH₂R^(′7a)         with R^(′7)a denoting a C₁ alkoxy radical, a hydroxyl group —OH,         a —CH₂COOH group, a group —CH(R^(5b))OH, an amino group —NH₂, a         carboxylic group —COOH, a —CN group, a thioxo function.

According to one embodiment, in formula (I), L represents a single bond.

According to another embodiment, in formula (I), L represents a methylene group —CH₂.

Preferentially, in formula (I), L represents a single bond.

Preferably:

-   -   when R⁵ is linked to the nitrogen atom, then R⁵ represents a         hydrogen atom or a —CH₂COOH group,     -   when R⁵ is linked to a carbon atom belonging to the cyclic         radical X, then R⁵ represents a hydroxyl group —OH, a group         —CH(R^(5b))OH, an amino group —NH₂, a carboxylic group —COOH, a         halogen atom or a —CN group.

Preferentially, when X═X₁, then R³ is other than a halogen atom and when X═X₂, then R⁵ represents a hydrogen atom or a linear or branched C₁-C₃ alkyl radical optionally substituted with one or more halogen atoms.

More preferentially, R³ and R⁵ are different.

Even more preferentially, R³ represents a hydrogen atom or a group (CHR⁶)_(n)—(Z)_(o)—(CHR^(′6))_(p)—R⁷.

According to one embodiment, R³ represents a hydrogen atom or a group (CHR⁶)_(n)—(Z)_(o)—(CHR^(′6))_(p)—R⁷ and R⁵ represents a hydrogen atom or a linear or branched C₁-C₃ alkyl radical, optionally substituted with one or more halogen atoms.

Preferably, R¹¹ and R¹² are other than an —OH group.

According to one embodiment, in formula (I), R³ represents a hydrogen atom.

According to one embodiment, in formula (I), R³ represents a group (CHR⁶)_(n)—(Z)_(o)—(CHR^(′6))_(p)—R⁷.

According to one embodiment, in formula (I), the indices n, o and p, which may be identical or different, denote zero.

According to one embodiment, in formula (I), the indices n, o and p, which may be identical or different, denote a natural integer ranging from 1 to 3.

According to one embodiment, in formula (I), the indices n and p denote zero and the index o is equal to 1.

According to one embodiment, in formula (I), Z represents a methylene group —CH₂.

According to one embodiment, in formula (I), Z represents a divalent group-O—.

According to one embodiment, in formula (I), Z represents a divalent group-NH—.

According to one embodiment, in formula (I), R³ represents a group Z—R⁷, with Z having the meaning described previously.

According to a particular embodiment, in formula (I), R³ represents a group-CH₂—R⁷.

According to a particular embodiment, in formula (I), R³ represents a group-O—R⁷.

According to a particular embodiment, in formula (I), R³ represents a group-NH—R⁷.

According to one embodiment, in formula (I), R⁷ represents a heterocyclic radical chosen from the following heterocycles:

in which:

-   -   R_(7a) represents a linear or branched C₁-C₃ alkyl radical, a         linear or branched C₁-C₃ alkoxy radical or an amino radical         N(R^(8a))(R^(8b)),     -   R^(8a) and R^(8b), which may be identical or different, denote a         hydrogen atom, a linear or branched C₁-C₃ alkyl radical or a         cyclopropyl radical,     -   R₈ and R₉, which may be identical or different, represent a         hydrogen atom, a linear or branched C₁-C₃ alkyl radical, a         hydroxyl group —OH, a carbonyl function ═O, a C₁ hydroxyalkyl         radical (—CH₂OH), an amino group NH₂,     -   R₈ and R₉ can form, together with the carbon atoms to which they         are attached, a 5- to 7-membered carbocyclic ring.

According to one embodiment, in formula (I), R⁷ represents an aromatic or heteroaromatic radical chosen from:

in which:

-   -   R₁₀ represents a hydrogen atom or a halogen atom, one linear or         branched C₁-C₃ alkyl group optionally substituted with one or         more halogen atoms, one C₁-C₃ alkoxy group, one amino group         —NR¹¹R¹², one group —COR¹¹, one group —COOR¹¹, one amido group         —CONR¹¹R¹², one group —SOR¹¹, one group —SO₂R¹¹, one group         —NHCOR¹¹, one group —NHCOOR¹¹, one group —SOAR¹¹R¹² or one —CN         group; R¹¹ and R^(H), which may be identical or different,         representing a hydrogen atom or a linear or branched C₁-C₃ alkyl         radical optionally substituted with one or more halogen atoms,     -   m denotes zero or a natural integer ranging from 1 to 3.

Preferably, R¹¹ and R¹² are other than an —OH group.

Preferentially, R⁷ represents an aromatic or heteroaromatic radical as defined previously, optionally substituted with one or more methyl groups —CH₃, one or more methoxy groups —OCH₃, one or more hydroxyl groups —OH, one or more amino groups —NH₂, one or more —CH₂OH groups, one or more cyano groups —CN, one or more halogen atoms or one or more carbonyl functions.

According to one embodiment, the index m is equal to zero.

According to one embodiment, the index m denotes a natural integer ranging from 1 to 3.

Preferentially, the index m is equal to 1.

According to one embodiment, in formula (I), each of the elements Y¹, Y², Y³, Y⁴ and Y⁵ corresponds to a group —CR² with R² having the same meaning as that described previously.

According to one embodiment, in formula (I), each of the elements Y¹, Y², Y³, Y⁴ and Y⁵ corresponds to a group —CR² with R² representing a hydrogen atom.

According to one embodiment, in formula (I), each of the elements Y¹, Y², Y³, Y⁴ and Y⁵ corresponds to a group —CR² with R² representing a linear or branched C₁-C₅ alkyl radical.

According to one embodiment, in formula (I), each of the elements Q¹, Q² and Q³ represents a group —CR^(2a) with R^(2a) having the same meaning as that described previously.

According to one embodiment, in formula (I), each of the elements Q¹, Q² and Q³ represents a group —CR^(2a) with R^(2a) representing a hydrogen atom.

According to one embodiment, in formula (I), Q¹ and Q² represent a group —CR^(2a) with R^(2a) representing a hydrogen atom and Q³ represents a group —CR^(2a) with R^(2a) representing a linear or branched C₁-C₅ alkyl radical.

According to one embodiment, in formula (I), IV represents a linear or branched C₃-C₅ alkyl radical, preferably a branched C₃-C₅ and more preferentially branched C₄ alkyl radical.

According to one embodiment, in formula (I), IV represents a C₃-C₅ cycloalkyl radical, preferably cyclopropyl.

According to one embodiment, in formula (I), R¹ represents a linear or branched C₂-C₅ alkenyl radical.

According to one embodiment, in formula (I), R¹ represents a CH₂—(C₃-C₅)cycloalkyl radical.

According to one embodiment, in formula (I), R¹ represents a C₄-C₅ heterocycloalkyl radical.

According to one embodiment, in formula (I), R¹ represents a CH₂—(C₄-C₆)heterocycloalkyl radical, in particular a CH₂—(C₄-C₅)heterocycloalkyl radical.

Preferentially, R¹ represents a linear or branched C₃-C₅ alkyl radical, or a CH₂—(C₄-C₅)heterocycloalkyl radical.

According to one embodiment, R⁵ represents a hydrogen atom.

Preferably, the compound(s) of formula (I) are chosen from the compound(s) of formula (II), the pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof:

in which formula (II) R¹, R³, R⁵ and Y¹ to Y⁵ have the same meanings as in formula (I) described previously.

Preferentially, R³ represents a group (CHR⁶)_(n)—(Z)_(o)—(CHR^(′6))_(p)—R⁷ with R⁶, Z, R^(′6), R⁷ and the indices n, o and p having the same meanings as those indicated previously.

More preferentially, R³ represents a group CH₂—R⁷ with R⁷ representing a non-cationic heterocyclic radical.

Preferably, the compound(s) of formula (I) are chosen from the compound(s) of formula (III), the pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof:

in which formula (III) R¹, R³, R⁵ and Y¹ to Y⁵ have the same meanings as in formula (I) described previously.

Preferentially, in formula (III), R₅ represents a hydrogen atom or a linear or branched C₁-C₃ alkyl radical optionally substituted with one or more halogen atoms.

The compounds of formula (I) may be in the form of pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts are described in Berge et al., 1977, “Sels pharmaceutiquement acceptables” [Pharmaceutically acceptable salts], J. Pharm. Sci., Vol. 66, pages 1-19.

In particular, when the compounds of formula (I) according to the invention are in the form of salts, then the electrical neutrality of said compounds is ensured by an external cationic counterion Y which may be organic or mineral.

Y may be chosen from suitable inorganic cations such as alkali metal ions, especially Na⁺, K⁺, alkaline-earth metal ions, especially Ca²⁺, Mg²⁺, or alternatively other cations such as the aluminum ion Al³⁺.

Y may be chosen from suitable organic cations such as the ammonium ion NH₄+, substituted ammonium ions such as NH₃R⁺, NHR₂ ⁺, NR₄ ⁺ with R representing a C₁-C₄ alkyl radical.

In particular, the substituted ammonium ions are those chosen from derivatives of ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine and tromethamine, and amino acids such as lysine and arginine.

An example of a quaternary ammonium ion may be the ion N⁺ (CH₃)₄.

The compound(s) according to the invention may be in the form of the solvates thereof.

For the purposes of the present invention, the term “solvate” means a complex of solute (i.e. the compound according to the invention or the salt of said compound) and of solvent.

If the solvent is water, then the solvate may suitably be considered as a hydrate, for example, a hemihydrate, a monohydrate, a dihydrate, a trihydrate, etc.

For example, the solvates and/or hydrates may be obtained directly at the end of the synthetic process, the target compound being isolated in the form of a hydrate, for example a monohydrate or hemihydrate, or in the form of a solvate of the reaction solvent and/or purification solvent.

Unless otherwise indicated, any reference to a compound according to the invention also includes the solvate or the hydrate of the corresponding compound.

Typical processes for the preparation and identification of hydrates and solvates are well known to those skilled in the art: see, for example, pages 202-209 of K J Guillory, “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids” in Polymorphism in Pharmaceutical Solids, edition. Harry G. Britain, Vol. 95, Marcel Dekker, Inc., New York, 1999.

The hydrates and solvates may be isolated and characterized via methods known in the art, such as thermogravimetric analysis (TGA), TGA-mass spectroscopy, TGA-infrared spectroscopy, x-ray powder diffraction, Karl Fischer titration, high-resolution x-ray diffraction, and the like.

Preferably, the compound(s) of formula (Ia) are chosen from the compounds as described in the tables below, and also the pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof:

TABLE 1 IC50 IC50 hRORg hCD4/IL17

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (4-ethylphenyl)(1- ethylpropyl)amide Compound 1 B B

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid ((R)-sec-butyl)(4- ethylphenyl)amide Compound 2 B ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid cyclopropyl(4- ethylphenyl)amide Compound 3 C ND

3-bromo-1- (tetrahydropyran-2- yl)-1H-indazole-6- sulfonic acid (4- ethylphenyl) isobutylamide Compound 4 C ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (4- ethylphenyl)(tetrahy- dropyran-4- ylmethyl)amide Compound 5 C ND

1-((3,5- dimethylisoxazol-4- yl)methyl)-N-(4- ethylphenyl)-N- isobutyl-1H-indazole- 5-sulfonamide Compound 6 B ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid butyl(4- isopropylphenyl)amide Compound 7 B ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (4- ethylphenyl)propyl Compound 8 C ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid butyl(4- ethylphenyl)amide Compound 9 C ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (5-chloro-2- fluorophenyl) isobutylamide Compound 10 C ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (2,5- dimethylphenyl) isobutylamide Compound 11 B ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (3- methoxypyridin-2- yl)isobutylamide Compound 12 C ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (4-butyl-2- methylphenyl) isobutylamide Compound 13 B ND

N-(4-ethylphenyl)-N- isobutyl-1- ((tetrahydro-2H-pyran- 4-yl)methyl)-1H- indazole-5- sulfonamide Compound 14 C ND

3-amino-1H-indazole- 5-sulfonic acid (4- ethylphenyl) isobutylamide Compound 15 C ND

1-(tetrahydropyran-4- ylmethyl)-lH- indazole-5-sulfonic acid (4- ethylphenyl)oxetan-3- ylmethylamide Compound 16 C ND

1-(1-acetylpyrrolidin- 3-yl)-1H-indazole-5- sulfonic acid (4- ethylphenyl) isobutylamide Compound 17 B ND

3-(tetrahydropyran-4- ylmethoxy)-1- (tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (4- ethylphenyl) isobutylamide Compound 18 C ND

1-(3,5- dimethylisoxazol-4- ylmethyl)-1H- indazole-5-sulfonic acid (4- ethylphenyl) isobutylamide Compound 19 C ND

1-((1-acetylpyrrolidin- 3-yl)methyl)-N-(4- ethylphenyl)-N- isobutyl-1H-indazole- 5-sulfonamide Compound 20 C ND

N-(4-ethylphenyl)-N- isobutyl-1- ((tetrahydrofuran-3- yl)methyl)-1H- indazole-5- sulfonamide Compound 21 C ND

N-(4-ethylphenyl)-N- isobutyl-1- ((tetrahydro-2H-pyran- 3-yl)methyl)-1H- indazole-5- sulfonamide Compound 22 C ND

1-benzyl-N-(4- ethylphenyl)-N- isobutyl-1H-indazole- 5-sulfonamide Compound 23 C ND

N-(cyclobutylmethyl)- N-(4-ethylphenyl)-1- ((tetrahydro-2H-pyran- 4-yl)methyl)-1H- indazole-5- sulfonamide Compound 24 B ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (3- methoxyphenyl) isobutylamide Compound 25 C ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (3- methylphenyl) isobutylamide Compound 26 C ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (2,4- dimethylphenyl) isobutylamide Compound 27 B ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (3,5- dimethylphenyl) isobutylamide Compound 28 C ND

N-(4-ethylphenyl)-N- isopropyl-1- ((tetrahydro-2H-pyran- 4-yl)methyl)-1H- indazole-5- sulfonamide Compound 29 C ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid sec-butyl(4- ethylphenyl)amide Compound 30 B ND

N- (cyclopropylmethyl)- N-(4-ethylphenyl)-1- ((tetrahydro-2H-pyran- 4-yl)methyl)-1H- indazole-5- sulfonamide Compound 31 C ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid cyclopentyl(4- ethylphenyl)amide Compound 32 A ND

1-(tetrahydropyran-4- ylmethyl)-1H- indazole-5-sulfonic acid (4- ethylphenyl)(tetrahy- drofuran-3- ylmethyl)amide Compound 33 C ND

3-amino-1H-indazole- 5-sulfonic acid (4- ethylphenyl) isobutylamide Compound 34 C ND

N-(4-ethylphenyl)-N- isopentyl-1- ((tetrahydro-2H-pyran- 4-yl)methyl)-1H- indazole-5- sulfonamide Compound 35 C ND

N-(4-ethylphenyl)-N- isobutyl-1-(pyridin-4- ylmethyl)-1H- indazole-5- sulfonamide Compound 36 B A

N-(4-ethylphenyl)-N- isobutyl-1-(oxetan-3- ylmethyl)-1H- indazole-5- sulfonamide Compound 37 B A

1-(tetrahydropyran-4- yl)-1H-indazole-5- sulfonic acid (4- ethylphenyl) isobutylamide Compound 38 C ND

N-(4-ethylphenyl)-N- isobutyl-1- ((tetrahydro-2H-pyran- 4-yl)methyl)-1H- indazole-5- sulfonamide Compound 39 B B

TABLE 2 IC50 IC50 hRORg hCD4/IL17

1-(1-acetylpyrrolidin-3-yl)- 1H-indazole-5-sulfonic acid (4- ethylphenyl)isobutylamide Compound 40 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid cyclobutyl(4- ethylphenyl)amide Compound 41 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (5-fluoro-2- methylphenyl)isobutylamide Compound 42 B ND

1-(tetrahydropyran-4- ylmethyl)-2H-indazole-5- sulfonic acid (3-fluoro-2- methylphenyl)isobutylamide Compound 43 B ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (5- chlorophenyl)isobutylamide Compound 44 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (2- chlorophenyl)isobutylamide Compound 45 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (4- fluorophenyl)isobutylamide Compound 46 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid isobutyl-p- tolylamide Compound 47 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid isobutyl-o- tolylamide Compound 48 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (4- trifluoromethoxyphenyl) isobutylamide Compound 49 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid isobutyl(5- isopropylpyridin-2-yl)amide Compound 50 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (3- chlorobenzyl)isobutylamide Compound 51 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid isobutyl(2- trifluoromethylbenzyl)amide Compound 52 B ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (2-fluoro-6- methylphenyl)isobutylamide Compound 53 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (4-fluoro-2- methylphenyl)isobutylamide Compound 54 B ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid isobutyl(4- methoxy-2- methylphenyl)amide Compound 55 B ND

methyl 4-{isobutyl[1- (tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonyl]amino}-3- methylbenzoate Compound 56 B A

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (4-cyano-2- methylphenyl)isobutylamide Compound 57 B ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid isobutyl(2- trifluoromethylphenyl)amide Compound 58 B ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid isobutyl(4- trifluoromethylphenyl)amide Compound 59 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (3-chloro-2- hydroxymethylpropyl)(4- ethylphenyl)amide Compound 60 C ND

3-(tetrahydropyran-4- ylmethoxy)-1H-indazole-5- sulfonic acid (4- ethylphenyl)isobutylamide Compound 61 C ND

3-(tetrahydropyran-4- ylidenemethyl)-1H- indazole-6-sulfonic acid (4- ethylphenyl)isobutylamide Compound 62 A ND

3-(tetrahydropyran-4- ylmethyl)-1H-indazole-6- sulfonic acid (4- ethylphenyl)isobutylamide Compound 63 A A

3-morpholin-4-ylmethyl- 1H-indazole-6-sulfonic acid (4- ethylphenyl)isobutylamide Compound 64 A A

3-((cis)-2,6- dimethylmorpholin-4- ylmethyl)-1H-indazole-6- sulfonic acid (4- ethylphenyl)isobutylamide Compound 65 C ND

3-((S)-3-methylmorpholin- 4-ylmethyl)-1H-indazole-6- sulfonic acid (4- ethylphenyl)isobutylamide Compound 66 B ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid isobutyl-o- tolylamide Compound 69 C ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (2-cyano-4- methylphenyl)isobutylamide Compound 70 B ND

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (4,6- dimethylpyridin-3- yl)isobutylamide Compound 71 C C

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (4- dimethylaminophenyl) isobutylamide Compound 72 B B

1-(tetrahydropyran-4- ylmethyl)-1H-indazole-5- sulfonic acid (2-fluoro-4- methylphenyl)isobutylamide Compound 73 ND ND

methyl 5-[(4- ethylphenyl)isobutyl- sulfamoyl]-1- (tetrahydropyran-4- ylmethyl)-1H-indazole- 7-carboxylate Compound 74 C ND

5-[(4- ethylphenyl)isobutyl- sulfamoyl]-1- (tetrahydropyran-4- ylmethyl)-1H-indazole- 7-carboxylic acid amide Compound 75 ND ND ND: not determined; A: IC50 <100 nM.; B: IC50 = 100 nM-1 μM; C: IC50 >1 μM

In the tables described above, the median inhibitory concentrations IC₅₀ for the compounds belonging to formula (I) according to the invention have been given according to the following models:

GAL4-RORγTransactivation

The RORγtransactivation model was developed from the line HG5LN, which is a HeLa line that stably expresses a luciferase reporter gene controlled by a pentamer of the GAL4 recognition domain of yeast and of a β-globin promoter. The HG5LN line was stably transfected by the DNA-binding domain (DBD) of GAL4 fused to the ROR gamma ligand-binding domain (LBD). Molecules that inhibit the ROR gamma constitutive activity reduce the luciferase expression, thus leading to a reduction in the emitted luminescence.

The cells are seeded in 384-well plates (5000 cells in 45 μL/well of culture medium containing 10% fetal calf serum) and incubated for 4 hours at 37° C., 5% CO₂. 5 μL of the test molecules (compounds described in the tables described above) are then added to each well and the plates are incubated for 18 hours at a temperature of 37° C. under 5% of CO₂. 20 μL of luciferase substrate (Promega) are added to each well and the luminescence emitted is read by a microplate reader.

The luminescence units (“RLU”) are normalized by positive controls (“POS” containing a saturated concentration of N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl])benzenesulfonamide and negative controls (“NEG” containing DMSO): % inhibition=((RLU-NEG)*100)/(POS−NEG). The IC50 values are calculated from a 4-parameter logistic model using the XLFit software (IDBS).

IL-17A Secretion

This model allows measurement of the effect of inhibitors on IL-17A secretion by CD4+ cells. The cells are frozen CD4+ cells (STEMCELL, #70026), isolated from peripheral human blood and activated with anti-CD3 and anti-CD28 antibodies. The amount of IL-17a secreted is measured by the TR-FRET (kit HTRF® Human Interleukin 17A (Cisbio, #64H17PEC)) technology.

The cells are rapidly thawed, resuspended in their culture medium (RPMI inactivated 10% FCS) supplemented with soluble anti-CD28 antibodies and seeded (100 000 cells/well) in 96-well plates precoated with anti-CD3 antibodies. The cells are then treated with the ranges of inhibitors to be tested (from 1000 nM to 0.05 nM, 0.1% DMSO). After 4 days of incubation, the HTRF signal is measured using a microplate reader (λexcitation=337 nm, λemission=620/665 nm). The ratios obtained (665/620) are normalized relative to the positive control (cells activated with anti-CD3 and anti-CD28, 0.1% DMSO). The IC₅₀ values are calculated from a 4-parameter logistic model using the XLFit software (IDBS).

Preferentially, the compounds of formula (I) according to the invention are chosen from the following compounds:

TABLE 3

N-(4-ethylphenyl)-N-isobutyl-1- ((tetrahydro-2H-pyran-4-yl)methyl)-1H- indazole-5-sulfonamide Compound 39

N-(4-ethylphenyl)-N-isobutyl-1- (oxetan-3-ylmethyl)-1H-indazole-5- sulfonamide Compound 37

1-((1-acetylpyrrolidin-3-yl)methyl)-N- (4-ethylphenyl)-N-isobutyl-1H- indazole-5-sulfonamide Compound 20

1-((3,5-dimethylisoxazol-4-yl)methyl)- N-(4-ethylphenyl)-N-isobutyl-1H- indazole-5-sulfonamide Compound 24

1-(1-acetylpyrrolidin-3-yl)-1H-indazole- 5-sulfonic acid (4- ethylphenyl)isobutylamide Compound 40

N-(cyclobutylmethyl)-N-(4- ethylphenyl)-1-((tetrahydro-2H-pyran-4- yl)methyl)-1H-indazole-5-sulfonamide Compound 24

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid cyclopentyl(4- ethylphenyl)amide Compound 32

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid sec-butyl(4- ethylphenyl)amide Compound 30

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4- ethylphenyl)(1-ethylpropyl)amide Compound 1

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid butyl(4- isopropylphenyl)amide Compound 7

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (5-fluoro-2- methylphenyl)isobutylamide Compound 42

1-(tetrahydropyran-4-ylmethyl)-2H- indazole-5-sulfonic acid (3-fluoro-2- methylphenyl)isobutylamide Compound 43

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (2,5- dimethylphenyl)isobutylamide Compound 11

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4-butyl-2- methylphenyl)isobutylamide Compound 13

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (2,4- dimethylphenyl)isobutylamide Compound 27

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid isobutyl(2- trifluoromethylbenzyl)amide Compound 52

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4-fluoro-2- methylphenyl)isobutylamide Compound 54

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid isobutyl(4- methoxy-2-methylphenyl)amide Compound 55

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4-cyano-2- methylphenyl)isobutylamide Compound 57

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid isobutyl(2- trifluoromethylphenyl)amide Compound 58

3-(tetrahydropyran-4-ylmethyl)-1H- indazole-6-sulfonic acid (4- ethylphenyl)isobutylamide Compound 63

3-morpholin-4-ylmethyl-1H-indazole-6- sulfonic acid (4- ethylphenyl)isobutylamide Compound 64

3-((S)-3-methylmorpholin-4-ylmethyl)- 1H-indazole-6-sulfonic acid (4- ethylphenyl)isobutylamide Compound 66

In particular, among the compounds of formula (II), compounds 1, 2, 7, 11, 21, 24, 27, 30, 32, 36, 37, 39, 40, 42, 43, 52, 54, 55, 57 and 58 are preferred.

Among the compounds of formula (III), compounds 63, 64 and 66 are preferred.

The invention also relates to the compound(s) as described previously, as medicament and cosmetic.

Preferably, the invention also relates to the compound(s) as described previously, as medicament.

Specifically, the compounds according to the invention have advantageous pharmacological properties, given that said compounds modulate, i.e. inhibit, the activity of the RORγt receptor.

Thus, these properties make the compound(s) of formula (I) as described previously usable as medicament in the treatment of diseases mediated by the RORγt receptor.

Preferably, the compound(s) according to the invention are used in the treatment of inflammatory disorders and/or autoimmune diseases mediated by the RORγt receptor.

More preferentially, the compound(s) according to the invention, preferably those chosen from the compounds corresponding to formulae (II) and (III), are used in the treatment of acne, psoriasis and/or atopic dermatitis.

According to another embodiment, the compounds according to the invention are used for cosmetic treatment of the skin.

As indicated above, the present invention also relates to a pharmaceutical composition comprising, in a pharmaceutically acceptable medium, one or more compounds of formula (I) as defined previously, pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof.

Preferably, the pharmaceutical composition comprises one or more compounds chosen from the compounds of formulae (II) and (III) as defined previously, the pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof.

More preferentially, the pharmaceutical composition comprises one or more compounds of formula (I) chosen from compounds (1) to (75) defined previously.

Even more preferentially, the pharmaceutical composition comprises one or more compounds of formula (I) chosen from compounds 1, 2, 7, 11, 21, 24, 27, 30, 32, 36, 37, 39, 40, 42, 43, 52, 54, 55, 57, 58, 63, 64 and 66.

The pharmaceutical composition according to the invention as described previously may be administered orally or topically.

Preferably, the pharmaceutical composition is conditioned in a form that is suitable for topical application.

Via the oral route, the composition may be in the form of tablets, gel capsules, coated tablets, syrups, suspensions, solutions, powders, granules, emulsions, suspensions of microspheres or nanospheres or lipid or polymeric vesicles allowing controlled release.

Via the topical route, the pharmaceutical composition according to the invention is more particularly intended for treating the skin and mucous membranes, and may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks, pomades, powders, impregnated pads, syndets, solutions, gels, sprays, mousses, suspensions, sticks, shampoos or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or lipid or polymeric vesicles or of polymeric or gelled patches allowing controlled release.

The pharmaceutical composition is used for treating inflammatory disorders and/or autoimmune diseases mediated by the RORγt receptor.

More preferentially, the pharmaceutical composition is used in the treatment of acne and/or psoriasis.

The invention also relates to a process for treating diseases mediated by the RORγt receptor, comprising the administration, especially topically or orally, of a therapeutically effective amount of the pharmaceutical composition as defined above to a patient.

Preferably, the pharmaceutical composition is applied topically.

In accordance with another embodiment, a subject of the present invention is also one or more compounds of formula (II) as defined previously, the pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof:

in which formula (II) R¹, R³, R⁵ and Y¹ to Y⁵ have the same meanings as in formula (Ia) described previously.

Preferably, R³ represents a group (CHR⁶)_(n)—(Z)_(o)—(CHR^(′6))_(p)—R⁷ with R⁷ representing a non-cationic heterocyclic radical, a non-cationic cycloalkyl radical or a non-cationic aromatic or heteroaromatic radical as defined previously.

Among the compounds of formula (II), compounds 1, 2, 7, 11, 21, 24, 27, 30, 32, 36, 37, 39, 40, 42, 43, 52, 54, 55, 57 and 58 are preferred.

According to this embodiment, the invention also relates to the compound(s) of formula (II), as medicament and cosmetic.

In particular, the invention relates to the compound(s) of formula (II), for their use in the treatment of inflammatory disorders and/or autoimmune diseases mediated by the RORγt receptor.

Preferentially, a subject of the invention is the compound(s) of formula (II) for their use in the treatment of acne.

As a variant, a subject of the invention is also the compound(s) of formula (II) for their use in the treatment of psoriasis.

Alternatively, the compound(s) of formula (II) according to the invention are used for cosmetic treatment of the skin.

Furthermore, the invention also relates to a pharmaceutical composition comprising, in a pharmaceutically acceptable medium, one or more compounds of formula (II) as defined previously, pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof.

The pharmaceutical composition is used for treating inflammatory disorders and/or autoimmune diseases mediated by the RORγt receptor.

In accordance with another embodiment, a subject of the present invention is also one or more compounds of formula (III) as defined previously, the pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof:

in which formula (III) R¹, R³, R⁵ and Y¹ to Y⁵ have the same meanings as in formula (I) described previously.

Preferably, R³ represents a group (CHR⁶)_(n)—(Z)_(o)—(CHR^(′6))_(p)—R⁷ with R⁷ representing a non-cationic heterocyclic radical, a non-cationic cycloalkyl radical or a non-cationic aromatic or heteroaromatic radical as defined previously.

Among the compounds of formula (III), compounds 63, 64 and 66 are preferred.

According to this embodiment, the invention also relates to the compound(s) of formula (III), as medicament and cosmetic.

In particular, the invention relates to the compound(s) of formula (III), for their use in the treatment of inflammatory disorders and/or autoimmune diseases mediated by the RORγt receptor.

Preferentially, a subject of the invention is the compound(s) of formula (III) for their use in the treatment of acne.

As a variant, a subject of the invention is also the compound(s) of formula (III) for their use in the treatment of psoriasis.

Alternatively, the compound(s) of formula (III) according to the invention are used for cosmetic treatment of the skin.

Furthermore, the invention also relates to a pharmaceutical composition comprising, in a pharmaceutically acceptable medium, one or more compounds of formula (III) as defined previously, pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof.

The pharmaceutical composition is used for treating inflammatory disorders and/or autoimmune diseases mediated by the RORγt receptor.

The examples that follow serve to illustrate the invention without, however, being limiting in nature.

EXAMPLES

The standard LCMS method for analyzing the products is as follows: BEH C₁₈ standard column (150×2.1 mm, 1.8 μm) solvent: water/acetonitrile 0.1% formic acid. The preparative HPLC purifications were performed on a C18 column using, as eluent: 85% acetonitrile in water/0.1% formic acid.

Part I: Synthesis of the Bicyclic Sulfonamides Via Reaction Scheme 1

Example 1: Synthesis of N-(4-ethylphenyl)-N-isobutyl-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-sulfonamide

1. Synthesis of Intermediate 1.1

(4-ethylphenyl)isobutylamine

Isobutyraldehyde (6.33 ml; 0.07 mol) in tetrahydrofuran (100 ml) is added to 4-ethylaniline (9.48 ml; 0.08 mol). The mixture is stirred for 2 hours at room temperature. Sodium triacetoxyborohydride (22.04 g; 0.10 mol) is then added. The mixture is stirred overnight at room temperature, water (100 ml) are added and the resulting mixture is extracted with ethyl acetate (2×100 ml). The organic phases are combined, washed with brine (100 ml), dried (Na₂SO₄) and concentrated.

The crude product is chromatographed on silica gel (eluent: heptane/dichloromethane from 0 to 50% of dichloromethane). The (4-ethylphenyl)isobutylamine is obtained in the form of an orange oil with a compliant ¹H NMR.

MS: [M+H]=179

2. Synthesis of Intermediate 1.2

N-(4-ethylphenyl)-N-isobutyl-1H-indazole-5-sulfonamide

1H-Indazole-5-sulfonyl chloride (502 mg; 2.20 mmol) is added to (4-ethylphenyl)isobutylamine (300 mg; 1.69 mmol) and pyridine (820 μl; 10.15 mmol) in tetrahydrofuran (6 ml). The reaction medium is stirred for 7 hours at room temperature, hydrolyzed and extracted with ethyl acetate. The organic phases are combined, washed with brine, dried (Na₂SO₄) and concentrated.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 20 to 50% of ethyl acetate). The N-(4-ethylphenyl)-N-isobutyl-1H-indazole-5-sulfonamide (357 mg; 59%) is obtained in the form of a cream-colored solid with a compliant ¹H NMR.

MS: [M+H]=358

3. Synthesis of Compound 39 According to the Invention

4-(Bromomethyl)tetrahydropyran (90 mg; 0.50 mmol) is added to N-(4-ethylphenyl)-N-isobutyl-1H-indazole-5-sulfonamide (150 mg; 0.42 mmol) and cesium carbonate (137 mg; 0.42 mmol) in N,N-dimethylformamide (12 ml). The reaction medium is stirred for 30 minutes at a temperature of 100° C. under microwave irradiation, hydrolyzed and extracted with ethyl acetate. The organic phases are combined, washed with brine, dried (Na₂SO₄) and concentrated.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, 40% of ethyl acetate). The N-(4-ethylphenyl)-N-isobutyl-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-sulfonamide (97 mg; 50%) is obtained in the form of a white powder.

¹H NMR (400 MHz, DMSO-d6) δ 0.85 (d, J=6.6 Hz, 7H), 1.17 (t, J=7.6 Hz, 4H), 1.22-1.53 (m, 6H), 2.16-2.31 (m, 1H), 2.59 (q, J=7.6 Hz, 2H), 3.15-3.44 (m, 6H), 3.83 (ddd, J=11.5, 4.4, 2.0 Hz, 3H), 4.39 (d, J=7.2 Hz, 3H), 6.92-7.05 (m, 3H), 7.10-7.21 (m, 3H), 7.26 (dd, J=9.1, 1.8 Hz, 1H), 7.74 (d, J=9.3 Hz, 1H), 8.10 (d, J=1.7 Hz, 1H), 8.62 (s, 1H).

MS: [M+H]=456

With a procedure similar to that described for the synthesis of example 1, the compounds of the table below are obtained:

Example 2

N-(4-ethylphenyl)-N-isobutyl-1- ((tetrahydro-2H-pyran-3-yl)methyl)-1H- indazole-5-sulfonamide 1H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 Hz, 6H), 1.17 (t, J = 7.6 Hz, 3H), 1.23-1.35 (m, 1H), 1.35-1.53 (m, 2H), 1.54-1.72 (m, 2H), 2.08-2.23 (m, 1H), 2.59 (q, J = 7.6 Hz, 2H), 3.21 (dd, J = 11.2, 8.9 Hz, 1H), 3.32- 3.40 (m, 3H), 3.57-3.65 (m, 1H), 3.70 (dt, J = 10.9, 3.9 Hz, 1H), 4.31-4.48 (m, 2H), 6.96 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 7.45 (dd, J = 9.0, 1.8 Hz, 1H), 7.84- 7.89 (m, 1H), 8.09 (d, J = 1.8 Hz, 1H), 8.29 (d, J = 0.8 Hz, 1H) MS: [M + H] = 456 Example 3

N-(4-ethylphenyl)-N-isobutyl-1- ((tetrahydrofuran-3-yl)methyl)-1H- indazole-5-sulfonamide 1H NMR (DMSO-d6) δ: 0.85 (d, J = 6.7 Hz, 6H), 1.17 (t, J = 7.6 Hz, 3H), 1.42 (hept, J = 6.8 Hz, 1H), 1.57-1.73 (m, 1H), 1.83-2.00 (m. 1H), 2.60 (q, J = 7.6 Hz, 2H), 2.81 (hept, J = 7.1 Hz, 1H), 3.31-3.35 (m, 2H), 3.50 (dd, J = 8.6, 5.6 Hz, 1H), 3.60-3.71 (m, 2H), 3.81 (td, J = 8.1, 5.5 Hz, 1H), 4.36- 4.55 (m, 2H), 6.96 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H), 7.46 (dd, J = 8.8, 1.8 Hz, 1H), 7.90 (d, J = 9.0 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 8.30 (d, J = 0.9 Hz, 1H) MS: [M + H] = 442 Example 4

N-(4-ethylphenyl)-N-isobutyl-1-(oxetan-3- ylmethyl)-1H-indazole-5-sulfonamide 1H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 Hz, 6H), 1.17 (t, J = 7.6 Hz, 3H), 1.41 (non, J = 6.8 Hz, 1H), 2.60 (q, J = 7.6 Hz, 2H), 3.32 (m, 2H), 3.52 (tt, J = 7.6, 6.1 Hz, 1H), 4.49 (t, J = 6.2 Hz, 2H), 4.67 (dd, J = 7.8, 6.1 Hz, 2H), 4.77 (d, J = 7.2 Hz, 2H), 6.96 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H), 7.47 (dd, J = 8.9, 1.7 Hz, 1H), 7.91 (d, J = 8.9 Hz, 1H), 8.09 (d, J = 1.8 Hz, 1H), 8.29 (d, J = 0.9 Hz, 1H) MS: [M + H] = 428 Example 5

1-((1-acetylpyrrolidin-3-yl)methyl)-N-(4- ethylphenyl)-N-isobutyl-1H-indazole-5- sulfonamide 1H NMR (DMSO-d6, 80° C.) δ: 0.86 (d, J = 6.6 Hz, 6H), 1.19 (t, J = 7.6 Hz, 3H), 1.44- 1.60 (m, 1H), 1.60-1.83 (m, 1H), 1.83- 2.07 (m, 4H), 2.61 (q, J = 7.6 Hz, 2H), 2.72- 2.94 (m, 1H), 3.09-3.61 (m, 6H), 4.51 (d, J = 7.1 Hz, 2H), 6.99 (d, J = 8.5 Hz, 2H), 7.16 (d, J = 8.1 Hz, 2H), 7.49 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 8.9 Hz, 1H), 8.10 (s, 1H), 8.28 (s, 1H) MS: [M + H] = 483 Example 6

1-benzyl-N-(4-ethylphenyl)-N-isobutyl-1H- indazole-5-sulfonamide 1H NMR (DMSO-d6) δ: 0.84 (d, J = 6.7 Hz, 6H), 1.16 (t, J = 7.6 Hz, 3H), 1.41 (hept, J = 6.9 Hz, 1H), 2.59 (q, J = 7.6 Hz, 2H), 3.32 (m, 2H), 5.71 (s, 2H), 6.98 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 7.25 (dd, J = 9.2, 1.8 Hz, 1H), 7.31-7.43 (m, 5H), 7.73 (d, J = 9.1 Hz, 1H), 8.12 (dd, J = 1.9, 0.8 Hz, 1H), 8.75 (d, J = 1.0 Hz, 1H) MS: [M + H] = 448 Example 7

N-(4-ethylphenyl)-N-isobutyl-1-(pyridin-4- ylmethyl)-1H-indazole-5-sulfonamide 1H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 Hz, 6H), 1.17 (t, J = 7.6 Hz, 3H), 1.32-1.48 (m, 1H), 2.59 (q, J = 7.7 Hz, 2H), 3.33 (m, 2H), 5.82 (s, 2H), 6.96 (d, J = 7.9 Hz, 2H), 7.15 (dd, J = 11.8, 6.5 Hz, 4H), 7.48 (d, J = 8.9 Hz, 1H), 7.90 (d, J = 8.9 Hz, 1H), 8.14 (s, 1H), 8.39 (s, 1H), 8.52 (d, J = 5.1 Hz, 2H) MS: [M + H] = 449 Example 8

1-((3,5-dimethylisoxazol-4-yl)methyl)-N- (4-ethylphenyl)-N-isobutyl-1H-indazole-5- sulfonamide 1H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 Hz, 6H), 1.17 (t, J = 7.6 Hz, 3H), 1.41 (hept, J = 6.8 Hz, 1H), 2.11 (s, 3H), 2.44 (s, 3H), 2.59 (q, J = 7.6 Hz, 2H), 3.33 (s, 2H), 5.54 (s, 2H), 6.88-7.00 (m, 2H), 7.12-7.20 (m, 2H), 7.50 (dd, J = 8.9, 1.8 Hz, 1H), 7.88-8.01 (m, 1H), 8.10 (d, J = 2.0 Hz, 1H), 8.30 (d, J = 0.9 Hz, 1H) MS: [M + H] = 467

Example 9: Synthesis of 1-((1-acetylazetidin-3-yl)methyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide

1-(3-Hydroxymethylazetidin-1-yl)ethanone (0.27 g; 2.09 mmol) in toluene (1 ml) is added to a mixture of N-(4-ethylphenyl)-N-isobutyl-1H-indazole-5-sulfonamide (0.20 g; 0.56 mmol) and (triphenyl-λ⁵-phosphanylidene)acetonitrile (0.51 g; 1.68 mmol) in anhydrous toluene (3 ml) under argon. The reaction medium is stirred for 3 days at a temperature of 95° C., hydrolyzed and extracted with ethyl acetate. The organic phase is washed, dried (Na₂SO₄), filtered and concentrated.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 1-(1-acetylazetidin-3-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (136 mg; 51%) is obtained in the form of a pale yellow solid.

¹H NMR (DMSO-d6) δ: 0.85 (d, J=6.6 Hz, 6H), 1.17 (t, J=7.6 Hz, 3H), 1.42 (hept, J=6.8 Hz, 1H), 1.73 (s, 3H), 2.59 (q, J=7.6 Hz, 2H), 3.07-3.20 (m, 1H), 3.30-3.36 (m, 2H), 3.69 (dd, J=9.6, 5.6 Hz, 1H), 3.89 (t, J=9.0 Hz, 1H), 3.98 (dd, J=8.5, 5.5 Hz, 1H), 4.18 (t, J=8.4 Hz, 1H), 4.71 (d, J=7.3 Hz, 2H), 6.96 (d, J=8.4 Hz, 2H), 7.17 (d, J=8.4 Hz, 2H), 7.48 (dd, J=9.0, 1.7 Hz, 1H), 7.89-7.97 (m, 1H), 8.09 (d, J=1.7 Hz, 1H), 8.31 (d, J=0.9 Hz, 1H)

MS: [M+H]=469

Example 10: Synthesis of 1-(tetrahydropyran-4-yl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide

By following the same procedure as that for example 9, 1-(tetrahydropyran-4-yl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (22 mg; 36%) is obtained in the form of a white solid.

¹H NMR (DMSO-d6) δ: 0.85 (d, J=6.7 Hz, 6H), 1.18 (t, J=7.6 Hz, 3H), 1.41 (non, J=6.5 Hz, 1H), 1.85-1.97 (m, 2H), 2.15 (qd, J=12.3, 4.6 Hz, 2H), 2.60 (q, J=7.6 Hz, 2H), 3.30-3.32 (m, 2H), 3.58 (td, J=11.9, 2.0 Hz, 2H), 3.98-4.07 (m, 2H), 4.99 (td, J=11.3, 5.7 Hz, 1H), 6.98 (d, J=8.4 Hz, 2H), 7.18 (d, J=8.4 Hz, 2H), 7.44 (dd, J=8.9, 1.7 Hz, 1H), 7.94 (d, J=8.9 Hz, 1H), 8.11 (d, J=1.6 Hz, 1H), 8.32 (s, 1H)

MS: [M+H]=442

Example 11: Synthesis of 1-(1-acetylpyrrolidin-3-yl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide

A mixture of N-(4-ethylphenyl)-N-isobutyl-1H-indazole-5-sulfonamide (0.20 g; 0.56 mmol), cesium carbonate (0.27 g; 0.84 mmol) and 1-(3-bromopyrrolidin-1-yl)ethanone (0.13 g; 0.67 mmol) in 1-methyl-2-pyrrolidone (3 ml) is stirred for 5 hours at a temperature of 80° C., hydrolyzed and extracted with ethyl acetate. The organic phase is washed with water, dried (Na₂SO₄), filtered and concentrated.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 1-(1-acetylpyrrolidin-3-yl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (29 mg; 11%) is obtained in the form of a white solid.

Mixture of two conformers: ¹H NMR (DMSO-d6) δ: 0.85 (dd, J=6.7, 1.1 Hz, 6H), 1.18 (t, J=7.6 Hz, 3H), 1.33-1.50 (m, 1H), 2.01 (s, 3H), 2.60 (q, J=7.6 Hz, 2H), 3.34 (d, J=2.4 Hz, 2H), 3.46-3.54 (m, 1H), 3.59-3.65 (m, 1H), 3.65-3.72 (m, 1H), 3.76-3.82 (m, 1H), 3.85 (dd, J=12.3, 6.8 Hz, 1H), 4.05 (dd, J=10.8, 7.0 Hz, 1H), 5.57 (ddt, J=27.8, 11.5, 6.2 Hz, 1H), 6.90-7.03 (m, 2H), 7.16-7.21 (m, 2H), 7.49 (ddd, J=8.8, 5.4, 1.7 Hz, 1H), 7.92 (t, J=9.0 Hz, 1H), 8.11 (dd, J=3.4, 1.6 Hz, 1H), 8.32-8.41 (m, 1H)

MS: [M+H]=469

With a procedure similar to that for intermediate 1.1, corresponding to a reductive amination between 1 equivalent of aldehyde and 1.15 equivalents of aniline in tetrahydrofuran in the presence of 1.45 equivalents of sodium triacetoxyborohydride, the anilines of the table below are obtained:

Intermediate 12.1

cyclopropylmethyl(4- ethylphenyl)amine (300 mg; 46%) obtained in the form of an orange oil with a compliant ¹H NMR. MS: [M + H] = 176 Intermediate 13.1

cyclobutylmethyl(4- ethylphenyl)amine (400 mg; 56%) obtained in the form of an orange oil with a compliant ¹H NMR. MS: [M + H] = 190 Intermediate 14.1

cyclopentylmethyl(4- ethylphenyl)amine (19.3 g; 56%) obtained in the form of an amber-colored oil with a compliant ¹H NMR. MS: [M + H] = 190 Intermediate 15.1

cyclobutylmethyl(4- ethylphenyl)amine (700 mg; 97%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 176 Intermediate 16.1

(tetrahydrofuran-3-ylmethyl)(4- ethylphenyl)amine (600 mg; 78%) obtained in the form of an orange oil with a compliant ¹H NMR. MS: [M + H] = 206 Intermediate 17.1

sec-butyl(4-ethylphenyl)amine (600 mg; 90%) obtained in the form of an orange oil with a compliant ¹H NMR. MS: [M + H] = 178 Intermediate 18.1

(4-ethylphenyl)(3-methylbutyl)amine (250 mg; 32%) obtained in the form of an orange oil with a compliant ¹H NMR. MS: [M + H] = 192 Intermediate 19.1

4-ethyl-N-isopropylaniline (300 mg; 49%) obtained in the form of an orange oil with a compliant ¹H NMR. MS: [M + H] = 165 Intermediate 20.1

(4-ethylphenyl)(1-ethylpropyl)amine (700 mg; 98%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 192 Intermediate 21.1

ethyl(4-ethylphenyl)amine commercial Intermediate 22.1

propyl(4-ethylphenyl)amine (450 mg; 73%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 165 Intermediate 23.1

butyl(4-ethylphenyl)amine (650 mg; 98%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 178 Intermediate 24.1

(2,2,2-trifluoroethyl)(4- ethylphenyl)amine commercial Intermediate 25.1

isobutyl(4-isopropylphenyl)amine (600 mg; 93%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 193 Intermediate 26.1

(5-chloro-2- fluorophenyl)isobutylamine (350 mg; 56%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 202 Intermediate 27.1

(5-fluoro-2- methylphenyl)isobutylamine (802 mg; 61%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 182 Intermediate 28.1

(3-fluoro-2- methylphenyl)isobutylamine (408 mg; 31%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 182 Intermediate 29.1

(5-chlorophenyl)isobutylamine (655 mg; 100%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 185 Intermediate 30.1

(2-chlorophenyl)isobutylamine (655 mg; 100%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 184 Intermediate 31.1

(4-fluorophenyl)isobutylamine (684 mg; 100%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 169 Intermediate 32.1

(4-methylphenyl)isobutylamine (876 mg; 63%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 164 Intermediate 33.1

isobutyl-o-tolylamine (972.8 mg; 70%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 164 Intermediate 34.1

(2,5-dimethylphenyl)isobutylamine (700 mg; 97%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 179 Intermediate 35.1

(4-butyl-2- methylphenyl)isobutylamine (520 mg; 85%) obtained in the form of a clear yellow oil with a compliant ¹H NMR. MS: [M + H] = 220 Intermediate 36.1

(2,4-dimethylphenyl)isobutylamine (1.15 g; 83%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 179 Intermediate 37.1

(3.5-dimethylphenyl)isobutylamine (600 mg; 82%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 179 Intermediate 38.1

(3-methylphenyl)isobutylamine (600 mg; 79%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 164 Intermediate 39.1

(3-methoxyphenyl)isobutylamine (600 mg; 82%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 181 Intermediate 40.1

(4- trifluoromethoxyphenyl)isobutylamine (600 mg; 100%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 235 Intermediate 41.1

isobutyl(5-isopropylpyridin-2- yl)amine (600 mg; 93%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 193 Intermediate 42.1

(3-methoxypyridin-2-yl)isobutylamine (450 mg; 68%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 181 Intermediate 43.1

(3-chlorobenzyl)isobutylamine (500 mg; 68%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 198 Intermediate 44.1

(3-methoxypyridin-2-yl)isobutylamine (600 mg; 100%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 232 Intermediate 45.1

(2-fluoro-6- methylphenyl)isobutylamine (560 mg; 44%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 182 Intermediate 46.1

(4-chloro-2- methylphenyl)isobutylamine (892 mg; 71%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 182 Intermediate 47.1

isobutyl(4-methoxy-2- methylphenyl)amine (980 mg; 77%) obtained in the form of an oil with a compliant ¹H NMR. MS: [M + H] = 193

With a procedure similar to that for intermediate 1.2, by reacting 1 equivalent of N-substituted anilines (derived from the above table or corresponding commercial products) with 1.3 equivalents of 1H-indazole-5-sulfonyl chloride in tetrahydrofuran (20 vol) in the presence of 6 equivalents of pyridine, the intermediates of the table below are obtained:

Intermediate 12.2

1H-indazole-5-sulfonic acid cyclopropylmethyl(4- ethylphenyl)amide (450 mg; 81%) is obtained in the form of colorless oil with a compliant ¹H NMR. MS: [M + H] = 356 Intermediate 13.2

1H-indazole-5-sulfonic acid cyclobutylmethyl(4- ethylphenyl)amide (590 mg; 55%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 370 Intermediate 14.2

1H-indazole-5-sulfonic acid cyclopentyl(4-ethylphenyl)amide (250 mg; 47%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 370 Intermediate 15.2

1H-indazole-5-sulfonic acid cyclobutyl(4-ethylphenyl)amide (80 mg; 51%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 356 Intermediate 16.2

1H-indazole-5-sulfonic acid (4- ethylphenyl)(tetrahydrofuran-3- ylmethyl)amide (800 mg; 78%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 386 Intermediate 17.2

1H-indazole-5-sulfonic acid sec- butyl(4-ethylphenyl)amide (310 mg; 56%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 358 Intermediate 18.2

1H-indazole-5-sulfonic acid (4- ethylphenyl)(3-methylbutyl)amide (220 mg; 50%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 372 Intermediate 19.2

1H-indazole-5-sulfonic acid (4- ethylphenyl)isopropylamide (400 mg; 70%) obtained in the form of a colorless oil with a compliant ¹H NMR MS: [M + H] = 344 Intermediate 20.2

1H-indazole-5-sulfonic acid (4- ethylphenyl)(1-ethylpropyl)amide (40 mg; 25%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 372 Intermediate 21.2

1H-indazole-5-sulfonic acid ethyl(4- ethylphenyl)amide (160 mg; 55%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 330 Intermediate 22.2

1H-indazole-5-sulfonic acid (4- ethylphenyl)propylamide (400 mg; 46%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 344 Intermediate 23.2

1H-indazole-5-sulfonic acid (4- ethylphenyl)butylamide (800 mg; 67%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 358 Intermediate 25.2

1H-indazole-5-sulfonic acid isobutyl(4-isopropylphenyl)amide (800 mg; 76%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 372 Intermediate 26.2

1H-indazole-5-sulfonic acid (5- chloro-2-fluorophenyl)isobutylamide (120 mg; 20%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 381 Intermediate 27.2

1H-indazole-5-sulfonic acid (5- fluoro-2-methylphenyl)isobutylamide (267 mg; 53%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 362 Intermediate 28.2

1H-indazole-5-sulfonic acid (3- fluoro-2-methylphenyl)isobutylamide (137 mg; 38%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 362 Intermediate 29.2

1H-indazole-5-sulfonic acid (5-chlorophenyl)isobutylamide (90 mg; 56%) obtained in the form of a white solid with a compliant ¹H NMR. MS: [M + H] = 364 Intermediate 31.2

1H-indazole-5-sulfonic acid (4- fluorophenyl)isobutylamide (100 mg; 66%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 348 Intermediate 32.2

1H-indazole-5-sulfonic acid isobutyl- p-tolylamide (770 mg; 81%) obtained in the form of a colorless oil with a compliant ¹H NMR MS: [M + H] = 344 Intermediate 33.2

1H-indazole-5-sulfonic acid isobutyl- o-tolylamide (481 mg; 46%) obtained in the form of a white solid with compliant ¹H NMR. MS: [M + H] = 344 Intermediate 34.2

1H-indazole-5-sulfonic acid (2,5- dimethylphenyl)isobutylamide (540 mg; 59%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 358 Intermediate 35.2

1H-indazole-5-sulfonic acid (4-butyl- 2-methylphenyl)isobutylamide (650 mg; 75%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 400 Intermediate 36.2

1H-indazole-5-sulfonic acid (2,4- dimethylphenyl)isobutylamide (500 mg; 55%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 381 Intermediate 37.2

1H-indazole-5-sulfonic acid (3,5- dimethylphenyl)isobutylamide (140 mg; 13%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 358 Intermediate 38.2

1H-indazole-5-sulfonic acid (3- methylphenyl)isobutylamide (310 mg; 27%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 344 Intermediate 39.2

1H-indazole-5-sulfonic acid (3- methoxyphenyl)isobutylamide (450 mg; 62%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 360 Intermediate 40.2

1H-indazole-5-sulfonic acid (4- trifluoromethoxyphenyl)isobutylamide (100 mg; 55%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 414 Intermediate 42.2

1H-indazole-5-sulfonic acid (3- methoxypyridin-2-yl)isobutylamide (300 mg; 37%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 361 Intermediate 43.2

1H-indazole-5-sulfonic acid (3- chlorobenzyl)isobutylamide (50 mg; 30%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 378 Intermediate 44.2

1H-indazole-5-sulfonic acid isobutyl(2- trifluoromethylbenzyl)amide (70 mg; 39%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 412 Intermediate 45.2

1H-indazole-5-sulfonic acid (2- fluoro-6-methylphenyl)isobutylamide (305 mg; 65%) obtained in the form of a white solid with a compliant ¹H NMR. MS: [M + H] = 362 Intermediate 46.2

1H-indazole-5-sulfonic acid (4- fluoro-2-methylphenyl)isobutylamide (307 mg; 65%) is obtained in the form of a yellowish solid with a compliant ¹H NMR. MS: [M − H] = 360 Intermediate 47.2

1H-indazole-5-sulfonic acid isobutyl(4-methoxy-2- methylphenyl)amide (437 mg; 89%) obtained in the form of a colorless oil with a compliant ¹H NMR. MS: [M + H] = 374 Intermediate 48.1

methyl 4-(1H-indazole-5- sulfonylamino)-3-methylbenzoate Obtained from the commercial amine. (480 mg; 63%) obtained in the form of a white solid with a compliant ¹H NMR. MS: [M − H] = 346 Intermediate 49.1

1H-indazole-5-sulfonic acid (4- cyano-2-methylphenyl)amide Obtained from the commercial amine. (330 mg; 80%) obtained in the form of a beige-colored solid with a compliant ¹H NMR. MS: [M − H] = 313

1. Synthesis of Intermediate 24.2

1H-indazole-5-sulfonic acid (4-ethylphenyl)(2,2,2-trifluoroethyl)amide

A mixture of 1H-indazole-5-sulfonyl chloride (200 mg; 0.88 mmol), pyridine (3 ml), potassium iodide (7.3 mg; 0.04 mmol), 4-dimethylaminopyridine (5.4 mg; 0.04 mmol) and N-(4-ethylphenyl)-N-(2,2,2-trifluoroethyl)amine hydrochloride (231 mg; 0.96 mmol) is stirred for 16 hours at a temperature of 100° C.

Silver(I) fluoride (5.6 mg; 0.04 mmol) is added to the reaction medium, which is stirred for 3 days at a temperature of 80° C.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 1H-indazole-5-sulfonic acid (4-ethylphenyl)(2,2,2-trifluoroethyl)amide (20 mg; 6%) is obtained in the form of a clear yellow oil.

MS: [M+H]=384

2. Synthesis of Intermediate 30.2

1H-indazole-5-sulfonic acid (2-chlorophenyl)isobutylamide

A mixture of 1H-indazole-5-sulfonyl chloride (200 mg; 0.88 mmol), pyridine (3.0 ml), potassium iodide (14 mg; 0.08 mmol), 4-dimethylaminopyridine (5.4 mg; 0.04 mmol) and (2-chlorophenyl)isobutylamine (600 mg; 3.27 mmol) is stirred for 3 days at a temperature of 100° C.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 1H-indazole-5-sulfonic acid (2-chlorophenyl)isobutylamide (10 mg; 3%) is obtained in the form of a yellow oil with a compliant ¹H NMR.

MS: [M+H]=364

3. Synthesis of Intermediate 41.2

1H-indazole-5-sulfonic acid cyclopropylmethyl(4-ethylphenyl)amide

With the same procedure as that used for intermediate 30.2, 1H-indazole-5-sulfonic acid cyclopropylmethyl(4-ethylphenyl)amide (40 mg; 12%) is obtained in the form of a yellow oil with a compliant ¹H NMR.

MS: [M+H]=373

4. Synthesis of Intermediate 45.2

1H-indazole-5-sulfonic acid (2-fluoro-6-methylphenyl)isobutylamide

(2-Fluoro-6-methylphenyl)isobutylamine (520 mg; 2.87 mmol) is added to a solution of 1H-indazole-5-sulfonyl chloride (297.4 mg; 1.30 mmol) in acetonitrile (1.25 ml) and the reaction medium is stirred for 40 minutes with microwave irradiation at a temperature of 100° C. The reaction medium is treated with 1N hydrochloric acid solution and extracted with ethyl acetate. The organic phases are combined, washed with water, dried (MgSO₄), filtered and concentrated.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 60% of ethyl acetate). The 1H-indazole-5-sulfonic acid (2-fluoro-6-methylphenyl)isobutylamide (305 mg; 65%) is obtained in the form of a white solid with a compliant ¹H NMR.

MS: [M+H]=362

With a procedure similar to that described for the synthesis of example 1, the addition of 1.2 equivalents of 4-(bromomethyl)tetrahydropyran to 1 equivalent of N-substituted 1H-indazole-5-sulfonamide (prepared previously) in N,N-dimethylformamide in the presence of 1 equivalent of cesium carbonate under microwave irradiation at 100° C. leads to the compounds in the table below:

Example 12

N-(cyclopropylmethyl)-N-(4- ethylphenyl)-1-((tetrahydro-2H-pyran- 4-yl)methyl)-1H-indazole-5-sulfonamide ¹H NMR (DMSO-d6) δ: 0.23-0.35 (m, 2H), 0.64-0.77 (m, 1H), 1.12 (t, J = 7.6 Hz, 3H), 1.19-1.37 (m, 4H), 2.10 (dtd, J = 11.1, 6.9, 3.4 Hz, 1H), 2.54 (q, J = 7.6 Hz, 2H), 3.17 (td, J = 11.3, 3.0 Hz, 2H), 3.38 (d, J = 7.0 Hz, 2H), 3.76 (ddd, J = 11.5, 4.4, 2.2 Hz, 2H), 4.32 (d, J = 7.1 Hz, 2H), 6.89-6.97 (m, 2H), 7.11 (d, J = 8.3 Hz, 2H), 7.45 (dd, J = 8.9, 1.7 Hz, 1H), 7.85 (dt, J = 8.8, 0.9 Hz, 1H), 8.06 (d, J = 1.6 Hz, 1H), 8.23 (d, J = 0.9 Hz, 1H). MS: [M + H] = 454 Example 13

N-(cyclobutylmethyl)-N-(4- ethylphenyl)-1-((tetrahydro-2H-pyran- 4-yl)methyl)-1H-indazole-5-sulfonamide ¹H NMR (DMSO-d6) δ: 1.17 (t, J = 7.6 Hz, 3H), 1.24-1.45 (m, 4H), 1.54-1.66 (m, 2H), 1.69-1.89 (m, 4H), 2.10-2.30 (m, 2H), 2.59 (q, J = 7.6 Hz, 2H), 3.27 (td, J = 11.6, 2.4 Hz, 2H), 3.56 (d, J = 7.5 Hz, 2H), 3.83 (ddd, 2H), 4.40 (d, J = 7.1 Hz, 2H), 6.88-6.96 (m, 2H), 7.15 (d, J = 8.3 Hz, 2H), 7.31 (dd, J = 9.1, 1.8 Hz, 1H), 7.75 (d, J = 9.1 Hz, 1H), 8.12-8.14 (m, 1H), 8.63 (d, J = 0.9 Hz, 1H) MS: [M + H] = 468 Example 14

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid cyclopentyl(4- ethylphenyl)amide ¹H NMR (DMSO-d6) δ: 1.12-1.26 (m, 5H), 1.26-1.49 (m, 9H), 1.74 (dd, J = 12.2, 6.9 Hz, 2H), 2.61 (q, J = 7.6 Hz, 2H), 3.24 (td, J = 11.3, 2.9 Hz, 2H), 3.82 (ddd, J = 11.5, 4.3, 2.2 Hz, 2H), 4.39 (d, J = 7.0 Hz, 2H), 4.46-4.57 (m, 1H), 6.87- 6.92 (m, 2H), 7.17-7.23 (m, 2H), 7.69 (dd, J = 9.0, 1.8 Hz, 1H), 7.91-7.96 (m, 1H), 8.21 (d, J = 1.6 Hz, 1H), 8.30 (d, J = 0.9 Hz, 1H) MS: [M + H] = 468 Example 15

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid cyclobutyl(4- ethylphenyl)amide ¹H NMR (DMSO-d6) δ: 1.18 (t, J = 7.6 Hz, 3H), 1.23-1.62 (m, 6H), 1.76 (dq, J = 12.0, 9.7 Hz, 2H), 2.05 (dddd, J = 9.4, 7.4, 5.1, 2.5 Hz, 2H), 2.10-2.26 (m, 1H), 2.61 (q, J = 7.6 Hz, 2H), 3.24 (td, J = 11.3, 2.9 Hz, 2H), 3.82 (ddd, J = 11.5, 4.3, 2.1 Hz, 2H), 4.38 (dd, J = 8.5, 6.5 Hz, 3H), 6.80 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H), 7.48 (dd, J = 9.0, 1.8 Hz, 1H), 7.90 (d, J = 9.1 Hz, 1H), 8.11 (d, J = 1.6 Hz, 1H), 8.31 (s, 1H) MS: [M + H] = 454 Example 16

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4- ethylphenyl)(tetrahydrofuran-3- ylmethyl)amide ¹H NMR (DMSO-d6) δ: 1.18 (t, J = 7.6 Hz, 3H), 1.25-1.43 (m, 4H), 1.58 (dq, J = 13.2, 6.8 Hz, 1H), 1.76-1.90 (m, 1H), 2.06 (p, J = 5.9 Hz, 1H), 2.11-2.22 (m, 1H), 2.61 (q, J = 7.6 Hz, 2H), 3.24 (td, J = 11.3, 3.0 Hz, 2H), 3.42 (dd, J = 8.6, 5.2 Hz, 1H), 3.48-3.62 (m, 4H), 3.71 (td, J = 8.1, 5.4 Hz, 1H), 3.76-3.89 (m, 2H), 4.39 (d, J = 7.0 Hz, 2H), 6.91-7.00 (m, 2H), 7.14 -7.24 (m, 2H), 7.48 (dd, J = 9.0, 1.7 Hz, 1H), 7.87-7.95 (m, 1H), 8.12 (d, J = 1.6 Hz, 1H), 8.30 (d, J = 1.0 Hz, 1H) MS: [M + H] = 484 Example 17

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid sec-butyl(4- ethylphenyl)amide ¹H NMR (DMSO-d6) δ: 0.85 (t, J = 7.3 Hz, 3H), 0.93 (d, J = 6.7 Hz, 3H), 1.12- 1.25 (m, 5H), 1.26-1.44 (m, 4H), 2.62 (q, J = 7.6 Hz, 2H), 3.24 (td, J = 11.3, 3.2 Hz, 2H), 3.82 (ddd, J = 11.5, 4.3, 2.3 Hz, 2H), 4.19 (dt, J = 7.8, 6.4 Hz, 1H), 4.39 (d, J = 7.1 Hz, 2H), 6.91 (d, J = 8.3 Hz, 2H), 7.21 (d, J = 8.3 Hz, 2H), 7.68 (dd, J = 8.9, 1.8 Hz, 1H), 7.94 (dt, J = 9.0, 0.9 Hz, 1H), 8.20 (d, J = 1.6 Hz, 1H), 8.30 (d, J = 0.9 Hz, 1H) MS: [M + H] = 456 Example 18

N-(4-ethylphenyl)-N-isopentyl-1- ((tetrahydro-2H-pyran-4-yl)methyl)- 1H-indazole-5-sulfonamide ¹H NMR (DMSO-d6) δ: 0.80 (d, J = 6.6 Hz, 6H), 1.17 (t, J = 7.6 Hz, 5H), 1.25- 1.42 (m, 4H), 1.61 (hept, J = 6.7 Hz, 1H), 2.09-2.24 (m, 1H), 2.60 (q, J = 7.6 Hz, 2H), 3.23 (td, J = 11.2, 3.1 Hz, 2H), 3.55 (t, J = 7.1 Hz, 2H), 3.81 (dt, J = 11.5, 3.3 Hz, 2H), 4.38 (d, J = 7.1 Hz, 2H), 6.90- 6.99 (m, 2H), 7.12-7.22 (m, 2H), 7.47 (dd, J = 9.0, 1.7 Hz, 1H), 7.87-7.96 (m, 1H), 8.11 (d, J = 2.0 Hz, 1H), 8.30 (d, J = 1.1 Hz, 1H) MS: [M + H] = 470 Example 19

N-(4-ethylphenyl)-N-isopropyl-1- ((tetrahydro-2H-pyran-4-yl)methyl)- 1H-indazole-5-sulfonamide ¹H NMR (DMSO-d6) δ: 0.95 (d, J = 6.7 Hz, 6H), 1.19 (t, J = 7.6 Hz, 3H), 1.26- 1.45 (m, 4H), 2.63 (q, J = 7.6 Hz, 2H), 3.24 (td, J = 11.3, 3.0 Hz, 2H), 3.82 (ddd, J = 11.5, 4.3, 2.2 Hz, 2H), 4.39 (d, J = 7.1 Hz, 2H), 4.47 (p, J = 6.7 Hz, 1H), 6.90- 6.98 (m, 2H), 7.22 (d, J = 8.3 Hz, 2H), 7.70 (dd, J = 8.9, 1.8 Hz, 1H), 7.90-7.99 (m, 1H), 8.22 (d, J = 1.6 Hz, 1H), 8.30 (d, J = 0.9 Hz, 1H). MS: [M + H] = 442 Example 20

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4- ethylphenyl)(1-ethylpropyl)amide ¹H NMR (DMSO-d6) δ: 0.85 (t, J = 7.3 Hz, 6H), 1.07-1.22 (m, 5H), 1.30 (ddd, J = 20.0, 9.0, 5.7 Hz, 6H), 2.16 (s, 1H), 2.61 (q, J = 7.6 Hz, 2H), 3.23 (td, J = 11.2, 3.4 Hz, 2H), 3.81 (d, J = 11.1 Hz, 2H), 3.91 (q, J = 6.5 Hz, 1H), 4.39 (d, J = 7.2 Hz, 2H), 6.86-6.93 (m, 2H), 7.21 (d, J = 8.3 Hz, 2H), 7.93 (d, J = 9.0 Hz, 1H), 8.15 (d, J = 1.5 Hz, 1H), 8.29 (d, J = 0.9 Hz, 1H). MS: [M + H] = 470 Example 22

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4- ethylphenyl)propylamide ¹H NMR (DMSO-d6) δ: 0.83 (t, J = 7.3 Hz, 3H), 1.17 (t, J = 7.6 Hz, 3H), 1.25- 1.44 (m, 6H), 2.24 (ddt, J = 10.9, 7.5, 3.8 Hz, 1H), 2.60 (q, J = 7.5 Hz, 2H), 3.26 (td, J = 11.6, 2.5 Hz, 2H), 3.50 (t, J = 6.9 Hz, 2H), 3.83 (ddd, J = 11.5, 4.5, 2.0 Hz, 2H), 4.40 (d, J = 7.1 Hz, 2H), 6.93-7.02 (m, 2H), 7.17 (d, J = 8.3 Hz, 2H), 7.29 (dd, J = 9.1, 1.8 Hz, 1H), 7.70-7.80 (m, 1H), 8.12 (dd, J = 1.9, 0.8 Hz, 1H), 8.62 (d, J = 11.0 Hz, 1H) MS: [M + H] = 442 Example 23

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid butyl(4- ethylphenyl)amide ¹H NMR (DMSO-d6) δ: 0.74-0.88 (m, 3H), 1.17 (t, J = 7.6 Hz, 3H), 1.23-1.45 (m, 8H), 2.24 (ddt, J = 11.0, 7.6, 3.8 Hz, 1H), 2.60 (q, J = 7.6 Hz, 2H), 3.26 (td, J = 11.5, 2.5 Hz, 2H), 3.54 (q, J = 4.4 Hz, 2H), 3.83 (ddd, J = 11.5, 4.3, 2.0 Hz, 2H), 4.40 (d, J = 7.2 Hz, 2H), 6.93-7.01 (m, 2H), 7.17 (d, J = 8.3 Hz, 2H), 7.28 (dd, J = 9.1, 1.8 Hz, 1H), 7.74 (dd, J = 9.0, 1.0 Hz, 1H), 8.11-8.14 (m, 1H), 8.62 (d, J = 0.9 Hz, 1H). MS: [M + H] = 456 Example 25

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid butyl(4- isopropylphenyl)amide ¹H NMR (DMSO-d6) δ: 0.85 (d, J = 6.7 Hz, 6H), 1.19 (d, J = 6.9 Hz, 6H), 1.25- 1.50 (m, 5H), 2.11-2.22 (m, 1H), 2.88 (hept, J = 6.8 Hz, 1H), 3.23 (td, J = 11.3, 2.9 Hz, 2H), 3.82 (ddd, J = 11.6, 4.4, 2.2 Hz, 2H), 4.38 (d, J = 7.1 Hz, 2H), 6.94- 7.03 (m, 2H), 7.20 (d, J = 8.4 Hz, 2H), 7.44 (dd, J = 8.9, 1.8 Hz, 1H), 7.85-7.94 (m, 1H), 8.09 (d, J = 1.7 Hz, 1H), 8.29 (d, J = 0.9 Hz, 1H) MS: [M + H] = 470 Example 26

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (5-chloro-2- fluorophenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 6H), 1.21-1.49 (m, 5H), 2.17 (dd, J = 10.5, 5.9 Hz, 1H), 3.23 (td, J = 11.1, 3.3 Hz, 2H), 3.76-3.87 (m, 2H), 4.40 (d, J = 7.0 Hz, 2H), 7.15 (dd, J = 6.5, 2.7 Hz, 1H), 7.35 (dd, J = 10.1, 8.9 Hz, 1H), 7.50 (ddd, J = 8.8, 4.1, 2.6 Hz, 1H), 7.56 (dd, J = 9.0, 1.8 Hz, 1H), 7.92-7.99 (m, 1H), 8.20 (d, J = 1.7 Hz, 1H), 8.33 (d, J = 1.0 Hz, 1H). MS: [M + H] = 480 Example 27

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (5-fluoro-2- methylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.77 (d, J = 6.7 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H), 1.22- 1.49 (m, 5H), 2.07-2.25 (m, 1H), 2.27 (s, 3H), 3.13 (dd, J = 13.2, 4.7 Hz, 1H), 3.23 (td, J = 11.2, 3.4 Hz, 2H), 3.43 (dd, J = 13.2, 9.1 Hz, 1H), 3.81 (dt, J = 11.5, 3.2 Hz, 2H), 4.40 (d, J = 7.1 Hz, 2H), 6.45 (dd, J = 10.1, 2.7 Hz, 1H), 7.12 (td, J = 8.3, 2.7 Hz, 1H), 7.35 (dd, J = 8.6, 6.6 Hz, 1H), 7.51 (dd, J = 8.9, 1.8 Hz, 1H), 7.91- 7.99 (m, 1H), 8.16 (d, J = 1.6 Hz, 1H), 8.34 (d, J = 0.9 Hz, 1H). MS: [M + H] = 460 Example 28

1-(tetrahydropyran-4-ylmethyl)-2H- indazole-5-sulfonic acid (3-fluoro-2- methylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.77 (d, J = 6.7 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H), 1.18- 1.52 (m, 5H), 2.08-2.27 (m, 4H), 3.13 (dd, J = 13.1, 4.8 Hz, 1H), 3.23 (td, J = 11.2, 3.1 Hz, 2H), 3.46 (dd, J = 13.2, 9.0 Hz, 1H), 3.73-3.88 (m, 2H), 4.39 (d, J = 7.1 Hz, 2H), 6.52 (d, J = 8.1 Hz, 1H), 7.06- 7.26 (m, 2H), 7.52 (dd, J = 8.9, 1.8 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 8.32 (d, J = 1.0 Hz, 1H). MS: [M + H] = 460 Example 29

1-tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (5- chlorophenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 Hz, 6H), 1.21-1.50 (m, 5H), 3.23 (td, J = 11.2, 3.2 Hz, 2H), 3.38 (d, J = 7.3 Hz, 2H), 3.80 (s, 2H), 4.38 (d, J = 7.1 Hz, 2H), 7.08 (dt, J = 7.0, 2.0 Hz, 1H), 7.13 (t, J = 1.9 Hz, 1H), 7.34-7.40 (m, 2H), 7.41- 7.44 (m, 1H), 7.91 (d, J = 8.9 Hz, 1H), 8.11 (d, J = 1.7 Hz, 1H), 8.31 (d, J = 1.0 Hz, 1H). MS: [M + H] = 462 Example 30

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (2- chlorophenyl)isobutylamide ¹H NMR (400 MHz, CDCl3) δ 0.86 (t, J = 6.2 Hz, 6H), 1.37 (td, J = 10.9, 9.9, 4.0 Hz, 4H), 1.55 (dt, J = 13.5, 6.8 Hz, 2H), 2.22 (s, 1H), 3.28 (td, J = 11.1, 4.0 Hz, 2H), 3.36 (dd, J = 7.2, 1.8 Hz, 2H), 3.89 (dt, J = 11.6, 3.3 Hz, 2H), 4.22 (d, J = 7.1 Hz, 2H), 7.19 (m, 3H), 7.25-7.30 (m, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.61 (dd, J = 8.9, 1.7 Hz, 1H), 8.03 (s, 1H), 8.07 (d, J = 1.6 Hz, 1H). MS: [M + H] = 462 Example 31

1-(tetrahydrouyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4- fluorophenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 Hz, 6H), 1.23-1.48 (m, 5H), 2.16 (ddd, J = 11.0, 6.9, 4.2 Hz, 1H), 3.23 (td, J = 11.3, 2.9 Hz, 2H), 3.35 (s, 2H), 3.82 (ddd, J = 11.5, 4.5, 2.2 Hz, 2H), 4.38 (d, J = 7.0 Hz, 2H), 7.05-7.22 (m, 4H), 7.45 (dd, J = 8.9, 1.7 Hz, 1H), 7.90 (d, J = 8.9 Hz, 1H), 8.07 (d, J = 1.7 Hz, 1H), 8.30 (s, 1H). MS: [M + H] = 446 Example 32

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid isobutyl-p- tolylamide ¹H NMR (DMSO-d6) δ: 0.85 (d, J = 6.7 Hz, 6H), 1.23-1.48 (m, 5H), 2.05-2.25 (m, 1H), 2.29 (s, 3H), 3.24 (td, J = 11.3, 2.8 Hz, 3H), 3.32 (td, 2H), 3.82 (dd, J = 11.3, 3.7 Hz, 2H), 4.38 (d, J = 7.1 Hz, 2H), 6.89-6.95 (m, 2H), 7.13 (d, J = 8.1 Hz, 2H), 7.45 (dd, J = 8.9, 1.8 Hz, 1H), 7.89 (d, J = 8.8 Hz, 1H), 8.07 (d, J = 1.6 Hz, 1H), 8.30 (s, 1H). MS: [M + H] = 442 Example 33

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid isobutyl-o- tolylamide ¹H NMR (DMSO-d6) δ: 0.76 (d, J = 6.7 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H), 1.24- 1.50 (m, 5H), 2.07-2.26 (m, 1H), 2.30 (s, 3H), 3.13 (dd, J = 13.2, 4.9 Hz, 1H), 3.24 (td, J = 11.0, 2.9 Hz, 2H), 3.45 (dd, J = 13.1, 8.9 Hz, 1H), 3.82 (dd, J = 13.4, 2.4 Hz, 2H), 4.40 (d, J = 7.1 Hz, 2H), 6.62 (dd, J = 8.1, 1.3 Hz, 1H), 7.08 (td, J = 7.7, 1.7 Hz, 1H), 7.24 (td, J = 7.5, 1.3 Hz, 1H), 7.31 (dd, J = 7.8, 1.6 Hz, 1H), 7.53 (dd, J = 8.9, 1.8 Hz, 1H), 7.93 (d, J = 8.9 Hz, 1H), 8.13 (s, 1H), 8.32 (s, 1H). MS: [M + H] = 442 Example 34

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (2,5- dimethylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.77 (d, J = 6.7 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H), 1.26- 1.38 (m, 4H), 1.44 (dtd, J = 8.9, 6.7, 4.8 Hz, 1H), 2.03 (s, 3H), 2.12-2.22 (m, 1H), 2.23 (s, 3H), 3.07 (dd, J = 13.1, 4.8 Hz, 1H), 3.19-3.27 (m, 2H), 3.43 (dd, J = 13.1, 8.9 Hz, 1H), 3.81 (dq, J = 10.8, 3.4 Hz, 2H), 4.41 (d, J = 7.0 Hz, 2H), 6.29 (d, J = 1.7 Hz, 1H), 7.04 (dd, J = 7.8, 1.8 Hz, 1H), 7.17 (d, J = 7.7 Hz, 1H), 7.49 (dd, J = 9.0, 1.7 Hz, 1H), 7.93 (dt, J = 9.0, 0.9 Hz, 1H), 8.13 (d, J = 1.6 Hz, 1H), 8.32 (d, J = 0.9 Hz, 1H) MS: [M + H] = 456 Example 35

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4-butyl-2- methylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.75 (d, J = 6.6 Hz, 3H), 0.90 (t, J = 7.3 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H), 1.24-1.47 (m, 8H), 1.48- 1.59 (m, 2H), 2.16 (s, 1H), 2.25 (s, 3H), 3.09 (dd, J = 13.1, 4.9 Hz, 1H), 3.24 (td, J = 11.1, 3.2 Hz, 2H), 3.37-3.46 (m, 1H), 3.77-3.88 (m, 2H), 4.39 (d, J = 7.0 Hz, 2H), 6.52 (d, J = 8.2 Hz, 1H), 6.88 (dd, J = 8.2, 2.2 Hz, 1H), 7.11 (d, J = 2.1 Hz, 1H), 7.52 (dd, J = 9.0, 1.7 Hz, 1H), 7.85- 7.98 (m, 1H), 8.13 (d, J = 1.6 Hz, 1H), 8.31 (d, J = 0.9 Hz, 1H) MS: [M + H] = 498 Example 36

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (2,4- dimethylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.76 (d, J = 6.7 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H), 1.22- 1.48 (m, 5H), 2.09 (d, J = 4.8 Hz, 1H), 2.11-2.21 (m, 1H), 2.25 (d, J = 4.1 Hz, 6H), 3.08 (dd, J = 13.1, 4.8 Hz, 1H), 3.24 (td, J = 11.2, 3.2 Hz, 2H), 3.43 (dd, J = 13.1, 8.9 Hz, 1H), 3.76-3.87 (m, 2H), 4.40 (d, J = 7.0 Hz, 2H), 6.48 (d, J = 8.1 Hz, 1H), 6.87 (dd, J = 8.1, 2.1 Hz, 1H), 7.11 (d, J = 2.1 Hz, 1H), 7.53 (dd, J = 9.0, 1.7 Hz, 1H), 7.90-7.96 (m, 1H), 8.13 (d, J = 1.7 Hz, 1H), 8.32 (d, J = 0.9 Hz, 1H) MS: [M + H] = 456 Example 37

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (3,5- dimethylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 Hz, 6H), 1.22-1.38 (m, 4H), 1.44 (hept, J = 6.8 Hz, 1H), 2.16 (s, 7H), 3.23 (td, J = 11.1, 3.6 Hz, 2H), 3.29 (d, J = 7.3 Hz, 2H), 3.76-3.85 (m, 2H), 4.39 (d, J = 7.0 Hz, 2H), 6.58-6.63 (m, 2H), 6.94 (s, 1H), 7.42 (dd, J = 8.8, 1.7 Hz, 1H), 7.87- 7.92 (m, 1H), 8.09 (d, J = 1.6 Hz, 1H), 8.31 (d, J = 0.9 Hz, 1H) MS: [M + H] = 456 Example 38

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (3- methylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 Hz, 6H), 1.23-1.52 (m, 5H), 2.22 (s, 4H), 3.23 (td, J = 11.3, 3.2 Hz, 2H), 3.77- 3.87 (m, 2H), 4.38 (d, J = 7.1 Hz, 2H), 6.78-6.89 (m, 2H), 7.10-7.15 (m, 1H), 7.20 (t, J = 7.7 Hz, 1H), 7.85-7.93 (m, 1H), 8.08 (d, J = 1.6 Hz, 1H), 8.30 (d, J = 0.9 Hz, 1H) MS: [M + H] = 442 Example 39

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (3- methoxyphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.86 (d, J = 6.6 Hz, 6H), 1.21-1.38 (m, 4H), 1.45 (hept, J = 6.8 Hz, 1H), 3.23 (td, J = 11.3, 3.2 Hz, 2H), 3.61 (s, 3H), 3.81 (dt, J = 11.7, 2.7 Hz, 2H), 4.38 (d, J = 7.0 Hz, 2H), 6.53 (t, J = 2.3 Hz, 1H), 6.66 (ddd, J = 7.9, 2.0, 0.9 Hz, 1H), 6.89 (ddd, J = 8.3, 2.5, 0.9 Hz, 1H), 7.24 (t, J = 8.1 Hz, 1H), 7.46 (dd, J = 8.9, 1.7 Hz, 1H), 7.88-7.94 (m, 1H), 8.10 (d, J = 1.6 Hz, 1H), 8.30 (d, J = 0.8 Hz, 1H) MS: [M + H] = 458 Example 40

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4- trifluoromethoxyphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.85 (d, J = 6.6 Hz, 6H), 1.24-1.47 (m, 5H), 2.10-2.20 (m, 1H), 3.23 (td, J = 11.3, 2.9 Hz, 2H), 3.37 (d, J = 7.4 Hz, 2H), 3.80 (s, 2H), 4.38 (d, J = 7.1 Hz, 2H), 7.20-7.26 (m, 2H), 7.32-7.37 (m, 2H), 7.43 (dd, J = 9.0, 1.8 Hz, 1H), 7.91 (d, J = 9.0 Hz, 1H), 8.10 (d, J = 1.7 Hz, 1H), 8.30 (d, J = 0.9 Hz, 1H); MS: [M + H] = 512 Example 41

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid isobutyl(5- isopropylpyridin-2-yl)amide ¹H NMR (Chloroform-d) δ: 0.82 (d, J = 6.7 Hz, 6H), 1.20 (s, 6H), 1.30-1.44 (m, 4H), 2.15-2.28 (m, 1H), 2.87 (p, J = 7.0 Hz, 1H), 3.28 (td, J = 11.5, 3.0 Hz, 2H), 3.42 (d, J = 7.3 Hz, 2H), 3.86-3.93 (m, 2H), 4.18 (d, J = 7.2 Hz, 2H), 7.29-7.33 (m, 1H), 7.40 (dd, J = 9.0, 1.7 Hz, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.55 (dd, J = 8.3, 2.5 Hz, 1H), 8.01 (d, J = 0.8 Hz, 1H), 8.04 (d, J = 1.8 Hz, 1H), 8.08 (d, J = 2.5 Hz, 1H). MS: [M + H] = 471 Example 42

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (3- methoxypyridin-2-yl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.86 (d, J = 6.6 Hz, 6H), 1.20-1.37 (m, 4H), 1.57 (hept, J = 6.9 Hz, 1H), 2.03-2.24 (m, 1H), 3.12- 3.26 (m, 3H), 3.42 (s, 3H), 3.53 (d, J = 7.1 Hz, 2H), 3.71-3.87 (m, 2H), 4.37 (d, J = 7.1 Hz, 2H), 6.69 (d, J = 8.1 Hz, 1H), 7.12 (d, J = 7.5 Hz, 1H), 7.46 (dd, J = 9.0, 1.8 Hz, 1H), 7.73-7.82 (m, 1H), 7.88 (dd, J = 9.0, 1.0 Hz, 1H), 8.19 (d, J = 1.6 Hz, 1H), 8.29 (d, J = 0.9 Hz, 1H) MS: [M + H] = 459 Example 43

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (3- chlorobenzyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.70 (d, J = 6.6 Hz, 6H), 1.25-1.42 (m, 4H), 1.58 (dt, J = 13.6, 6.9 Hz, 1H), 2.92 (d, J = 7.6 Hz, 2H), 3.24 (td, J = 11.3, 3.2 Hz, 2H), 3.82 (d, J = 11.2 Hz, 2H), 4.33 (s, 2H), 4.40 (d, J = 7.1 Hz, 2H), 7.24-7.37 (m, 4H), 7.80 (dd, J = 9.0, 1.7 Hz, 1H), 7.96 (d, J = 8.9 Hz, 1H), 8.31 (d, J = 0.9 Hz, 1H), 8.37 (d, J = 1.7 Hz, 1H) MS: [M + H] = 476 Example 44

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid isobutyl(2- trifluoromethylbenzyl)amide ¹H NMR (DMSO-d6) δ: 0.70 (d, J = 6.6 Hz, 6H), 1.23-1.43 (m, 5H), 2.97 (d, J = 7.2 Hz, 2H), 3.24 (td, J = 11.3, 3.0 Hz, 2H), 3.82 (d, J = 10.7 Hz, 2H), 4.40 (d, J = 7.1 Hz, 2H), 4.48 (s, 2H), 7.50 (t, J = 7.6 Hz, 1H), 7.70 (q, J = 7.6 Hz, 2H), 7.78 (d, J = 7.9 Hz, 1H), 7.83 (dd, J = 8.9, 1.8 Hz, 1H), 7.98 (d, J = 8.9 Hz, 1H), 8.39 (d, J = 1.7 Hz, 1H) MS: [M + H] = 510 Example 45

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (2-fluoro-6- methylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.77 (d, J = 6.7 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H), 1.21- 1.39 (m, 4H), 1.41-1.57 (m, 1H), 2.08- 2.25 (m, 1H), 2.28 (s, 3H), 3.15 (dd, J = 13.7, 5.8 Hz, 1H), 3.23 (td, J = 11.0, 3.7 Hz, 2H), 3.45 (dd, J = 13.6, 7.9 Hz, 1H), 3.81 (dt, J = 11.4, 3.3 Hz, 2H), 4.39 (d, J = 7.0 Hz, 2H), 7.00 (ddd, J = 10.2, 8.3, 1.6 Hz, 1H), 7.15 (d, J = 7.6 Hz, 1H), 7.23- 7.36 (m, 1H), 7.63 (dd, J = 8.9, 1.8 Hz, 1H), 7.93 (d, J = 9.1 Hz, 1H), 8.21 (d, J = 1.6 Hz, 1H), 8.31 (d, J = 1.0 Hz, 1H) MS: [M + H] = 460 Example 46

1-(tetrahyropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4-fluoro-2- methylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.77 (d, J = 6.7 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H), 1.24- 1.50 (m, 5H), 2.11-2.24 (m, 1H), 2.29 (s, 3H), 3.10 (dd, J = 13.1, 4.8 Hz, 1H), 3.23 (td, J = 11.2, 3.2 Hz, 2H), 3.45 (dd, J = 13.2, 8.9 Hz, 1H), 3.82 (dt, J = 11.6, 2.7 Hz, 2H), 4.39 (d, J = 7.1 Hz, 2H), 6.66 (dd, J = 8.9, 5.5 Hz, 1H), 6.92 (td, J = 8.4, 3.1 Hz, 1H), 7.18 (dd, J = 9.8, 3.0 Hz, 1H), 7.53 (dd, J = 8.9, 1.7 Hz, 1H), 7.93 (dd, J = 9.0, 0.9 Hz, 1H), 8.13 (d, J = 1.6 Hz, 1H), 8.32 (d, J = 0.9 Hz, 1H) MS: [M + H] = 460 Example 47

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid isobutyl(4- methoxy-2-methylphenyl)amide 1H NMR (DMSO-d6) δ: 0.76 (d, J = 6.7 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H), 1.23- 1.53 (m, 5H), 2.08-2.21 (m, 1H), 2.24 (s, 3H), 3.07 (dd, J = 13.0, 4.8 Hz, 1H), 3.24 (td, J = 11.2, 3.2 Hz, 2H), 3.43 (dd, J = 13.1, 8.9 Hz, 1H), 3.73 (s, 3H), 3.82 (dt, J = 11.4, 3.3 Hz, 2H), 4.39 (d, J = 7.1 Hz, 2H), 6.51 (d, J = 8.8 Hz, 1H), 6.61 (dd, J = 8.8, 3.0 Hz, 1H), 6.85 (d, J = 2.9 Hz, 1H), 7.53 (dd, J = 8.9, 1.7 Hz, 1H), 7.87- 7.96 (m, 1H), 8.12 (d, J = 1.6 Hz, 1H), 8.31 (d, J = 0.9 Hz, 1H) MS: [M + H] = 472 Example 48

methyl 4-{isobutyl[1-(tetrahydropyran- 4-ylmethyl)-1H-indazole-5- sulfonyl]amino}-3-methylbenzoate ¹H NMR (DMSO-d6) δ: 0.76 (d, J = 6.7 Hz, 3H), 0.94 (d, J = 6.6 Hz, 3H), 1.23- 1.49 (m, 5H), 2.09-2.23 (m, 1H), 2.37 (s, 3H), 3.15 (dd, J = 13.2, 4.8 Hz, 1H), 3.24 (td, J = 11.2, 3.0 Hz, 2H), 3.46 (dd, J = 13.3, 8.9 Hz, 1H), 3.75-3.88 (m, 5H), 4.40 (d, J = 7.1 Hz, 2H), 6.80 (d, J = 8.3 Hz, 1H), 7.51 (dd, J = 8.9, 1.7 Hz, 1H), 7.65 (dd, J = 8.3, 2.2 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.93 (d, J = 8.9 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 8.32 (d, J = 0.9 Hz, 1H) MS: [M + H] = 500 Example 49

1-(tetrahydropyran-4-ylmethyl)-1H- indazole-5-sulfonic acid (4-cyano-2- methylphenyl)isobutylamide ¹H NMR (DMSO-d6) δ: 0.76 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 6.5 Hz, 3H), 1.21- 1.48 (m, 5H), 2.06-2.25 (m, 1H), 2.35 (s, 3H), 3.07-3.29 (m, 3H), 3.45 (dd, J = 13.3, 9.0 Hz, 1H), 3.82 (dd, J = 10.1, 3.2 Hz, 2H), 4.40 (d, J = 7.0 Hz, 2H), 6.88 (d, J = 8.3 Hz, 1H), 7.52 (dd, J = 9.0, 1.8 Hz, 1H), 7.59 (dd, J = 8.2, 2.1 Hz, 1H), 7.86 (d, J = 2.0 Hz, 1H), 7.94 (dd, J = 9.0, 0.9 Hz, 1H), 8.15 (d, J = 1.6 Hz, 1H), 8.33 (d, J = 1.0 Hz, 1H). MS: [M + H] = 467

Example 50: Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)(tetrahydropyran-4-ylmethyl)amide

1. Synthesis of Intermediate 50.1

1H-indazole-5-sulfonic acid (4-ethylphenyl)amide

A mixture of 1H-indazole-5-sulfonyl chloride (1.00 g; 4.39 mmol), pyridine (5.0 ml) and 4-ethylaniline (603 μl; 4.82 mmol) is stirred for 4 hours at 50° C. The reaction medium is diluted with ethyl acetate and extracted. The organic phase is washed with saturated ammonium chloride solution, with saturated sodium hydrogen carbonate solution and with water. It is dried (MgSO₄), filtered and concentrated to dryness.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 40% of ethyl acetate). The 1H-indazole-5-sulfonic acid (4-ethylphenyl)amide (1.32 g; 100%) is obtained in the form of an orange oil with a compliant ¹H NMR.

MS: [M+H]=302

2. Synthesis of Compound 5 According to the Invention

A mixture of 1H-indazole-5-sulfonic acid (4-ethylphenyl)amide (1.30 g; 4.31 mmol), cesium carbonate (2.11 g; 6.47 mmol) and 4-(bromomethyl)tetrahydropyran (680 μl; 5.18 mmol; 1.20 eq.) in N-methyl-2-pyrrolidone (10 ml) is stirred for 16 hours at a temperature of 50° C. The reaction medium is diluted with ethyl acetate (30 ml). The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml). The organic phase is dried (MgSO₄), filtered and concentrated.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)(tetrahydropyran-4-ylmethyl)amide (360 mg; 17%) is obtained in the form of a white solid.

¹H NMR (DMSO-d6) δ: 1.08-1.23 (m, 5H), 1.25-1.47 (m, 5H), 1.52-1.62 (m, 2H), 2.60 (q, J=7.5 Hz, 2H), 3.13 (td, J=11.6, 2.2 Hz, 2H), 3.23 (td, J=11.3, 3.0 Hz, 2H), 3.43 (d, J=7.2 Hz, 2H), 3.72-3.87 (m, 4H), 4.38 (d, J=7.1 Hz, 2H), 6.97 (d, J=8.4 Hz, 2H), 7.17 (d, J=8.4 Hz, 2H), 7.46 (dd, J=9.0, 1.7 Hz, 1H), 7.84-7.98 (m, 1H), 8.10 (d, J=1.7 Hz, 1H), 8.29 (d, J=0.9 Hz, 1H)

MS: [M+H]=498

-   -   Another fraction is obtained corresponding to the mixture below:

Intermediate 51.1: Mixture of N-(4-ethylphenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-sulfonamide and N-(4-ethylphenyl)-2-((tetrahydro-2H-pyran-4-yl)methyl)-2H-indazole-5-sulfonamide.

The mixture of N-(4-ethylphenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-sulfonamide and N-(4-ethylphenyl)-2-((tetrahydro-2H-pyran-4-yl)methyl)-2H-indazole-5-sulfonamide (170.00 mg; 10%) is obtained in the form of a solid with a compliant ¹H NMR.

MS: [M+H]=400

Example 51: Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid cyclopropyl(4-ethylphenyl)amide

A spatulaful of molecular sieves is added to a mixture of N-(4-ethylphenyl)-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-sulfonamide and N-(4-ethylphenyl)-2-((tetrahydro-2H-pyran-4-yl)methyl)-2H-indazole-5-sulfonamide (170 mg; 0.43 mmol), triethylamine (180 μl; 1.28 mmol), copper(II) acetate (232 mg; 1.28 mmol) and cyclopropylboronic acid (220 mg; 2.55 mmol) in dichloromethane (3 ml).

The reaction medium is stirred for 16 hours at room temperature under 1 atmosphere of oxygen and filtered through Celite, which is rinsed with dichloromethane (50 ml) and with water (20 ml). The organic phase is extracted, washed with a mixture (1/1) of aqueous ammonia and saturated NH₄Cl solution (2×50 ml) and then with water (50 ml), dried (MgSO₄), filtered and concentrated.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid cyclopropyl(4-ethylphenyl)amide 002 (40 mg; 21%) is obtained in the form of a white solid.

¹H NMR (DMSO-d6) δ: 0.62 (t, J=3.2 Hz, 2H), 0.76 (dt, J=7.1, 3.6 Hz, 2H), 1.14-1.22 (m, 4H), 1.23-1.42 (m, 4H), 2.16 (dd, J=10.8, 5.1 Hz, 1H), 2.58-2.71 (m, 3H), 3.17-3.29 (m, 3H), 3.76-3.89 (m, 2H), 4.38 (d, J=7.1 Hz, 2H), 6.87-7.02 (m, 2H), 7.15 (d, J=8.4 Hz, 2H), 7.46 (dd, J=8.8, 1.7 Hz, 1H), 7.91 (d, J=8.9 Hz, 1H), 8.15 (d, J=1.6 Hz, 1H), 8.33 (d, J=0.9 Hz, 1H)

MS: [M+H]=440

Example 52: Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid isobutyl(2-trifluoromethylphenyl)amide

1. Synthesis of Intermediate 52.1

1H-indazole-5-sulfonic acid (2-trifluoromethylphenyl)amide

A mixture of 1H-indazole-5-sulfonyl chloride (500.0 mg; 2.19 mmol), pyridine (3.0 ml) and 2-(trifluoromethyl)aniline (306.18 μl; 2.41 mmol) is stirred for 16 hours at a temperature of 40° C. The reaction medium is diluted with ethyl acetate and extracted. The organic phase is washed with saturated ammonium chloride solution, with saturated sodium hydrogen carbonate solution and with water. It is dried (MgSO₄), filtered and concentrated to dryness.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 40% of ethyl acetate).

The 1H-indazole-5-sulfonic acid (2-trifluoromethylphenyl)amide (300 mg; 40%) is obtained in the form of a white solid with a compliant ¹H NMR.

MS: [M+H]=342

2. Synthesis of Compound 58 According to the Invention

Cesium carbonate (30 mg; 1.32 mmol) and 4-(bromomethyl)tetrahydropyran (127 μl; 0.97 mmol) are added to a solution of 1H-indazole-5-sulfonic acid (2-trifluoromethylphenyl)amide (300 mg; 0.88 mmol) in 1-methyl-2-pyrrolidone (3 ml). The reaction medium is stirred for 16 hours at room temperature. 1-Bromo-2-methylpropane (287 μl; 2.64 mmol) is added and the reaction medium is stirred for 6 hours at 80° C. The reaction medium is diluted with ethyl acetate, washed with saturated ammonium chloride solution and then with saturated sodium hydrogen carbonate solution and with water. The organic phase is dried (MgSO₄), filtered and concentrated to dryness.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid isobutyl(2-trifluoromethylphenyl)amide (80 mg; 16%) is obtained in the form of a beige-colored solid.

¹H NMR (DMSO-d6) δ: 0.71 (d, J=6.7 Hz, 3H), 0.85-0.93 (m, 3H), 1.25-1.43 (m, 4H), 1.48 (dtd, J=8.8, 6.6, 4.6 Hz, 1H), 2.12-2.25 (m, 1H), 3.15 (dd, J=13.4, 4.6 Hz, 1H), 3.24 (td, J=10.8, 10.4, 2.2 Hz, 2H), 3.46 (dd, J=13.4, 8.8 Hz, 1H), 3.78-3.86 (m, 2H), 4.41 (d, J=7.1 Hz, 2H), 6.99 (dd, J=5.7, 3.7 Hz, 1H), 7.56 (dd, J=9.0, 1.7 Hz, 1H), 7.58-7.64 (m, 2H), 7.85 (dt, J=5.6, 3.7 Hz, 1H), 7.96 (d, J=8.9 Hz, 1H), 8.18-8.24 (m, 1H), 8.35 (s, 1H).

MS: [M+H]=496

Example 53: Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid isobutyl(4-trifluoromethylphenyl)amide

1. Synthesis of Intermediate 53.1

1H-indazole-5-sulfonic acid (4-trifluoromethylphenyl)amide

A mixture of 1H-indazole-5-sulfonyl chloride (250.0 mg; 1.10 mmol) and 4-(trifluoromethyl)aniline (388.6 μl; 2.41 mmol) in acetonitrile (1.7 ml) is stirred for 40 minutes at a temperature of 100° C. under microwave irradiation. The reaction medium is diluted with ethyl acetate and extracted.

The organic phase is washed with saturated ammonium chloride solution, with saturated sodium hydrogen carbonate solution and with water. It is dried (MgSO₄), filtered and concentrated to dryness.

The 1H-indazole-5-sulfonic acid (4-trifluoromethylphenyl)amide (297 mg; 79%) is obtained in the form of a yellowish solid with a compliant ¹H NMR.

MS: [M+H]=342

2. Synthesis of Compound 59 According to the Invention

With a procedure similar to that described for example 52, 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid isobutyl(4-trifluoromethylphenyl)amide (178 mg; 40%) is obtained in the form of a white solid.

¹H NMR (DMSO-d6) δ: 0.84 (d, J=6.6 Hz, 6H), 1.22-1.51 (m, 5H), 2.07-2.24 (m, 1H), 3.23 (td, J=11.4, 2.9 Hz, 2H), 3.42 (d, J=7.3 Hz, 2H), 3.81 (ddd, J=11.6, 4.2, 2.1 Hz, 2H), 4.37 (d, J=7.1 Hz, 2H), 7.37 (d, J=8.2 Hz, 2H), 7.43 (dd, J=8.9, 1.8 Hz, 1H), 7.73 (d, J=8.6 Hz, 2H), 7.91 (d, 1H), 8.13 (d, J=1.6 Hz, 1H), 8.31 (d, J=1.0 Hz, 1H).

MS: [M+H]=496

Example 54: Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (2-cyano-4-methylphenyl)isobutylamide

1. Synthesis of Intermediate 54.1

1H-indazole-5-sulfonic acid (2-cyano-4-methylphenyl)amide

With a procedure similar to that described for intermediate 53.1, 1H-indazole-5-sulfonic acid (2-cyano-4-methylphenyl)amide (342.4 mg; 100%) is obtained in the form of a yellowish solid with a compliant ¹H NMR.

MS: [M+H]=313

2. Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (2-cyano-4-methylphenyl)isobutylamide (compound 70)

With a procedure similar to that described for example 52, 1-(tetrahydropyran-4-ylmethyl)-2H-indazole-5-sulfonic acid (2-cyano-4-methylphenyl)isobutylamide (129.7 mg; 20%) is obtained in the form of a white solid.

¹H NMR (Chloroform-d) δ: 0.93 (d, J=6.7 Hz, 6H), 1.42-1.53 (m, 4H), 1.54-1.67 (m, 1H), 2.21-2.39 (m, 1H), 2.42 (s, 3H), 3.37 (td, J=11.3, 3.5 Hz, 2H), 3.45 (d, J=7.2 Hz, 2H), 3.98 (dt, J=11.7, 2.6 Hz, 2H), 4.32 (d, J=7.2 Hz, 2H), 7.25 (d, J=8.2 Hz, 1H), 7.41 (dd, J=8.2, 2.1 Hz, 1H), 7.45 (d, J=2.1 Hz, 1H), 7.52 (d, J=8.9 Hz, 1H), 7.78 (dd, J=8.9, 1.6 Hz, 1H), 8.15 (d, J=1.0 Hz, 1H), 8.18 (d, J=1.6 Hz, 1H).

MS: [M+H]=467

Example 55: Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4,6-dimethylpyridin-3-yl)isobutylamide

1. Synthesis of Intermediate 55.1

1H-indazole-5-sulfonic acid (4,6-dimethylpyridin-3-yl)amide

With a procedure similar to that described for intermediate 53.1, 1H-indazole-5-sulfonic acid (4,6-dimethylpyridin-3-yl)amide (151 mg; 46%) is obtained in the form of a yellowish solid with a compliant ¹H NMR.

MS: [M+H]=303

2. Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4,6-dimethylpyridin-3-yl)isobutylamide

With a procedure similar to that described for example 52, 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4,6-dimethylpyridin-3-yl)isobutylamide (17 mg; 7%) is obtained in the form of a white solid.

¹H NMR (DMSO-d6) δ: 0.78 (d, J=6.7 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 1.18-1.56 (m, 5H), 2.13-2.27 (m, 4H), 2.41 (s, 3H), 3.19-3.29 (m, 3H), 3.44 (dd, J=13.3, 8.6 Hz, 1H), 3.78-3.89 (m, 2H), 4.40 (d, J=7.0 Hz, 2H), 7.21 (s, 1H), 7.56 (dd, J=8.9, 1.8 Hz, 1H), 7.68 (s, 1H), 7.96 (d, J=8.8 Hz, 1H), 8.16 (d, J=1.7 Hz, 1H), 8.33 (s, 1H).

MS: [M+H]=457

Example 56: Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-dimethylaminophenyl)isobutylamide

1. Synthesis of Intermediate 56.1

1H-indazole-5-sulfonic acid (4-dimethylaminophenyl)amide

With a procedure similar to that described for intermediate 53.1, 1H-indazole-5-sulfonic acid (4-dimethylaminophenyl)amide (281 mg; 81%) is obtained in the form of a fluffy white solid with a compliant ¹H NMR.

MS: [M+H]=317

2. Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-dimethylaminophenyl)isobutylamide (compound 72)

With a procedure similar to that described for example 52, 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-dimethylaminophenyl)isobutylamide (19 mg; 4%) is obtained in the form of a white solid.

¹1-1H NMR (Chloroform-d) δ: 0.94 (d, J=6.7 Hz, 6H), 1.38-1.55 (m, 3H), 1.62 (dd, J=13.2, 6.3 Hz, 2H), 2.31 (dt, J=11.0, 5.6 Hz, 1H), 2.97 (s, 6H), 3.30 (d, J=7.3 Hz, 2H), 3.38 (td, J=11.3, 3.1 Hz, 2H), 3.99 (ddd, J=11.7, 4.4, 2.1 Hz, 2H), 4.31 (d, J=7.1 Hz, 2H), 6.60 (d, J=8.4 Hz, 2H), 6.84-6.91 (m, 2H), 7.41-7.46 (m, 1H), 7.60 (dd, J=8.9, 1.6 Hz, 1H), 8.08 (d, J=1.7 Hz, 1H), 8.11 (d, J=0.9 Hz, 1H).

MS: [M+H]=471

Example 57: Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (2-fluoro-4-methylphenyl)isobutylamide

1. Synthesis of Intermediate 57.1

1H-indazole-5-sulfonic acid (2-fluoro-4-methylphenyl)amide

With a procedure similar to that described for intermediate 53.1, 1H-indazole-5-sulfonic acid (2-fluoro-4-methylphenyl)amide (189 mg; 94%) is obtained in the form of a yellowish solid with a compliant ¹H NMR.

MS: [M+H]=306

2. Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (2-fluoro-4-methylphenyl)isobutylamide

With a procedure similar to that described for example 52, 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (2-fluoro-4-methylphenyl)isobutylamide (19 mg; 4%) is obtained in the form of a white solid.

¹H 1H NMR (Chloroform-d) δ: 0.93 (d, J=6.6 Hz, 6H), 1.47 (td, J=11.2, 10.7, 4.2 Hz, 3H), 1.54-1.69 (m, 2H), 2.30 (dd, J=10.7, 4.6 Hz, 1H), 2.36 (s, 3H), 3.24-3.47 (m, 5H), 3.95-4.03 (m, 2H), 4.31 (d, J=7.1 Hz, 2H), 6.82 (dd, J=11.5, 1.8 Hz, 1H), 6.94 (dd, J=8.2, 1.8 Hz, 1H), 7.16 (t, J=8.1 Hz, 1H), 7.45 (dt, J=9.0, 0.9 Hz, 1H), 7.67 (dd, J=8.9, 1.6 Hz, 1H), 8.13 (dd, J=9.3, 1.2 Hz, 2H).

MS: [M+H]=460

Part II: Synthesis of the Bicyclic Sulfonamides Via Reaction Scheme 2

Example 58: Synthesis of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)oxetan-3-ylmethylamide

1. Synthesis of Intermediate 58.1

2-chloromethyl-3-(4-ethylphenylamino)propan-1-ol

A mixture of 4-ethylaniline (513 μl; 4.13 mmol), oxetane-3-carbaldehyde (807.3 mg; 3.75 mmol) and tetrahydrofuran (2.5 ml) is stirred for 2 hours at room temperature. Sodium triacetoxyborohydride (1.19 g; 5.63 mmol) is added and the reaction medium is stirred for 16 hours at room temperature, hydrolyzed and extracted with ethyl acetate.

The organic phases are combined, washed with brine, dried (Na₂SO₄) and concentrated.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 40% of ethyl acetate). The 2-chloromethyl-3-(4-ethylphenylamino)propan-1-ol (340 mg; 40%) is obtained in the form of an orange oil with a ¹H NMR showing the opening of the oxetane.

MS: [M+H]=228

2. Synthesis of Intermediate 58.2

2-chloromethyl-3-(4-ethylphenylamino)propan-1-ol

A mixture of 1H-indazole-5-sulfonyl chloride (368.5 mg; 1.62 mmol), pyridine (3.0 ml; 37.17 mmol) and (4-ethylphenyl)oxetan-3-ylmethylamine (340 mg; 1.78 mmol) is stirred for 30 minutes at a temperature of 100° C. under microwave irradiation.

The reaction medium is diluted with ethyl acetate. The organic phase is washed with saturated ammonium chloride solution, with saturated sodium hydrogen carbonate solution and with water. It is dried (MgSO₄), filtered and concentrated to dryness.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 40% of ethyl acetate). The 1H-indazole-5-sulfonic acid (2-chloromethyl-3-hydroxypropyl)(4-ethylphenyl)amide (260 mg; 39%) is obtained in the form of a colorless oil with a compliant ¹H NMR.

MS: [M+H]=408

3. Synthesis of Intermediate 58.3

1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (3-chloro-2-hydroxymethylpropyl)(4-ethylphenyl)amide

A mixture of 1H-indazole-5-sulfonic acid (2-chloromethyl-3-hydroxypropyl)(4-ethylphenyl)amide (1.26 g; 0.64 mmol), cesium carbonate (0.31 mg; 0.96 mmol) and 4-(bromomethyl)tetrahydropyran (100 μl; 0.76 mmol) in N-methyl-2-pyrrolidone (4 ml) is stirred for 1 hour at a temperature of 80° C. The reaction medium is diluted with ethyl acetate (20 ml).

The organic phase is washed with saturated NH₄Cl solution, with saturated NaHCO₃ solution and with water. The organic phase is dried (MgSO₄), filtered and concentrated.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (3-chloro-2-hydroxymethylpropyl)(4-ethylphenyl)amide (100 mg; 31%) is obtained in the form of a colorless oil. ¹H NMR (DMSO-d6) δ: 1.18 (t, J=7.6 Hz, 3H), 1.25-1.43 (m, 4H), 1.73 (p, J=6.4 Hz, 1H), 2.61 (q, J=7.6 Hz, 2H), 3.23 (td, J=11.3, 3.0 Hz, 2H), 3.35-3.41 (m, 1H), 3.46-3.52 (m, 1H), 3.52-3.63 (m, 2H), 3.69 (qd, J=10.8, 4.9 Hz, 2H), 3.82 (ddd, J=11.4, 4.3, 2.2 Hz, 2H), 4.39 (d, J=7.0 Hz, 2H), 4.69 (t, J=5.1 Hz, 1H), 6.95-7.02 (m, 2H), 7.16-7.22 (m, 2H), 7.44 (dd, J=9.0, 1.8 Hz, 1H), 7.92 (d, J=8.9 Hz, 1H), 8.10 (d, J=1.6 Hz, 1H), 8.31 (s, 1H)

MS: [M+H]=506

4. Synthesis of Compound 16 According to the Invention

60% sodium hydride (17.4 mg; 0.43 mmol) is added to a solution of 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (3-chloro-2-hydroxymethylpropyl)(4-ethylphenyl)amide (100 mg; 0.20 mmol) in tetrahydrofuran (3 ml). The reaction medium is stirred for 1 hour at a temperature of 80° C. and then for 16 hours at a temperature of 30° C.

The reaction medium is diluted with ethyl acetate (20 ml). The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml). The organic phase is dried (MgSO₄), filtered and concentrated.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)oxetan-3-ylmethylamide (35.0 mg; 33%) is obtained in the form of a white solid.

¹H NMR (Methanol-d4) δ: 1.20 (t, J=7.6 Hz, 3H), 1.31-1.51 (m, 5H), 2.27 (tq, J=10.6, 6.2, 5.6 Hz, 1H), 2.62 (q, J=7.6 Hz, 2H), 3.01 (hept, J=7.3 Hz, 1H), 3.31-3.43 (m, 2H), 3.92 (d, J=7.7 Hz, 3H), 4.33-4.42 (m, 3H), 4.56-4.66 (m, 2H), 6.88 (d, J=8.2 Hz, 2H), 6.93-7.03 (m, 1H), 7.13 (d, J=8.1 Hz, 2H), 7.58 (dd, J=8.9, 1.7 Hz, 1H), 7.74 (d, J=8.8 Hz, 1H), 8.13 (s, 1H)

MS: [M+H]=470

Part III: Synthesis of the Bicyclic Sulfonamides Via Reaction Scheme 3

Example 59: Synthesis of methyl 5-[(4-ethylphenyl)isobutylsulfamoyl]-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-7-carboxylate

1. Synthesis of Intermediate 59.1

methyl 5-[(4-ethylphenyl)isobutylsulfamoyl]-1H-indazole-7-carboxylate

(4-Ethylphenyl)isobutylamine (417.5 mg; 2.35 mmol) is added to methyl 5-chlorosulfonyl-1H-indazole-7-carboxylate (300 mg; 1.07 mmol) in acetonitrile (4 ml). The reaction medium is stirred for 1 hour 20 minutes at a temperature of 100° C. under microwave irradiation.

The reaction medium is diluted with ethyl acetate, washed with 1N hydrochloric acid solution, and then with saturated sodium hydrogen carbonate solution and with water, dried (MgSO₄), filtered and concentrated.

The methyl 5-[(4-ethylphenyl)isobutylsulfamoyl]-1H-indazole-7-carboxylate (429.8 mg; 97%) is obtained in the form of a white solid with a compliant ¹H NMR.

MS: [M+H]=416

2. Synthesis of methyl 5-[(4-ethylphenyl)isobutylsulfamoyl]-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-7-carboxylate (compound 74)

4-(Bromomethyl)tetrahydropyran (97.6 μl; 0.74 mmol) is added to a mixture of methyl 5-[(4-ethylphenyl)isobutylsulfamoyl]-1H-indazole-7-carboxylate (280.0 mg; 0.67 mmol) and cesium carbonate (329 mg; 1 mmol) in 1-methyl-2-pyrrolidone (2.8 ml). The reaction medium is stirred at a temperature of 80° C. overnight.

The crude product is filtered and then purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The methyl 5-[(4-ethylphenyl)isobutylsulfamoyl]-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-7-carboxylate (223.4 mg; 63%) is obtained in the form of a white solid.

NMR (DMSO-d6) δ: 0.85 (d, J=6.6 Hz, 6H), 1.18 (t, J=7.6 Hz, 3H), 1.25 (dt, J=11.1, 5.3 Hz, 4H), 1.33-1.55 (m, 1H), 1.86-2.12 (m, 1H), 2.60 (q, J=7.6 Hz, 2H), 3.18 (td, J=11.1, 3.6 Hz, 2H), 3.35 (s, 2H), 3.79 (dt, J=11.4, 3.3 Hz, 2H), 3.93 (s, 3H), 4.57 (d, J=7.2 Hz, 2H), 6.93-7.06 (m, 2H), 7.12-7.23 (m, 2H), 7.80 (d, J=1.7 Hz, 1H), 8.37 (d, J=1.9 Hz, 1H), 8.48 (s, 1H)

MS: [M+H]=514

Example 60: Synthesis of 5-[(4-ethylphenyl)isobutylsulfamoyl]-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-7-carboxylic acid amide

Aqueous ammonia (1.05 ml) is added to a solution of methyl 5-[(4-ethylphenyl)isobutylsulfamoyl]-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-7-carboxylate (210.0 mg; 0.41 mmol) in N,N-dimethylformamide (1.05 ml).

The reaction medium is stirred for 3 days at room temperature and for 2 days at a temperature of 60° C. The reaction medium is diluted and extracted with dichloromethane. The organic phases are combined, dried (MgSO₄), filtered and concentrated to dryness.

The crude product is filtered and then purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.2% of ammonium carbonate). The 5-[(4-ethylphenyl)isobutylsulfamoyl]-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-7-carboxylic amide is obtained in the form of a white solid.

¹H NMR (Chloroform-d) δ: 0.94 (d, J=6.7 Hz, 6H), 1.25 (t, J=7.6 Hz, 3H), 1.38-1.51 (m, 4H), 1.59-1.69 (m, 1H), 2.08-2.21 (m, 1H), 2.67 (q, J=7.6 Hz, 2H), 3.25-3.39 (m, 4H), 3.90-4.01 (m, 2H), 4.59 (d, J=7.2 Hz, 2H), 5.75 (s, 1H), 6.00 (s, 1H), 6.94-7.00 (m, 2H), 7.11-7.18 (m, 2H), 7.62 (d, J=1.7 Hz, 1H), 8.15 (d, J=1.6 Hz, 1H), 8.19 (s, 1H) MS: [M+H]=499

Part IV: Synthesis of the Bicyclic Sulfonamides Via Reaction Scheme 4

Example 61: Synthesis of N-(4-ethylphenyl)-N-isobutyl-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-5-sulfonamide

1. Synthesis of Intermediate 60.1

3-bromo-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide

N-Bromosuccinimide (120 mg; 0.67 mmol) is added to a solution of 1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (200 mg; 0.56 mmol) in dichloromethane (5 ml). The reaction medium is stirred for 16 hours at room temperature, diluted with dichloromethane and extracted.

The organic phase is washed with saturated NH₄Cl solution, with saturated NaHCO₃ solution and with water, dried (MgSO₄), filtered and concentrated to dryness.

The 3-bromo-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (260 mg; 100%) is obtained in the form of a pale yellow solid with a compliant ¹H NMR.

MS: [M+H]=436

2. Synthesis of Intermediate 60.2

3-bromo-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide

A mixture of 3-bromo-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (260 mg; 0.60 mmol), cesium carbonate (388 mg; 1.19 mmol) and 4-(bromomethyl)tetrahydropyran (160 mg; 0.89 mmol) in N-methyl-2-pyrrolidone (3 ml) is stirred for 1 hour at a temperature of 80° C.

The reaction medium is diluted with ethyl acetate (30 ml). The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄), filtered and concentrated to dryness.

The 3-bromo-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (350 mg; 100%) is obtained in the form of a clear yellow oil with a compliant ¹H NMR.

MS: [M+H]=534

3. Synthesis of Compound 14 According to the Invention

2.5 M n-Butyllithium (900 μl; 2.24 mmol) is added, under argon, to a solution of 3-bromo-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (200 mg; 0.37 mmol) in tetrahydrofuran (3 ml) at a temperature of −78° C. The reaction medium is stirred for 30 minutes, paraformaldehyde (980 mg; 2.24 mmol) is then added, the temperature is allowed to return to room temperature and the medium is then stirred for 3 hours at a temperature of 60° C.

The reaction medium is hydrolyzed with 1M hydrochloric acid solution (5 ml) at room temperature for 10 days, and diluted with ethyl acetate (50 ml).

The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄), filtered and concentrated to dryness.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 3-hydroxymethyl-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (20 mg; 11%) is obtained in the form of a colorless oil.

¹H NMR (CD3OD-d4) δ: 0.90 (d, J=6.7 Hz, 7H), 1.22 (t, J=7.6 Hz, 3H), 1.27-1.58 (m, 4H), 1.71 (d, J=12.7 Hz, 2H), 2.16 (s, 1H), 2.64 (q, J=7.7 Hz, 2H), 3.35 (s, 2H), 3.41 (t, J=11.6 Hz, 2H), 3.96 (dd, J=11.9, 4.1 Hz, 2H), 4.66 (s, 2H), 6.92 (d, J=9.0 Hz, 1H), 7.00 (d, J=7.9 Hz, 2H), 7.16 (d, J=8.0 Hz, 2H), 7.44 (d, J=8.6 Hz, 1H), 8.03 (d, J=2.4 Hz, 1H)

MS: [M+H]=486

Part V: Synthesis of the Bicyclic Sulfonamides Via Reaction Scheme 5

Example 62: Synthesis of 3-amino-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide

1. Synthesis of Intermediate 61.1

5-[(4-ethylphenyl)isobutylsulfamoyl]-2-fluorobenzoic acid

A solution of (4-ethylphenyl)isobutylamine (0.80 g; 4.51 mmol) and pyridine (0.36 ml; 4.51 mmol) in tetrahydrofuran (8 ml) is added to a solution of 5-chlorosulfonyl-2-fluorobenzoic acid (1.44 g; 5.87 mmol) in tetrahydrofuran (8 ml).

The reaction medium is stirred for 19 hours at room temperature, hydrolyzed with aqueous 1N HCl solution and diluted with ethyl acetate.

The organic phase is washed with aqueous 1N HCl solution. The organic phase is dried (Na₂SO₄), filtered and concentrated.

The crude product is chromatographed on silica gel (eluent: dichloromethane/methanol, from 0 to 10% of methanol) and then by preparative HPLC (C18 column, eluent: from 60% to 70% of acetonitrile in water/0.1% of formic acid). The 5-[(4-ethylphenyl)isobutylsulfamoyl]-2-fluorobenzoic acid (0.56 g; 33%) is obtained in the form of an off-white solid with a compliant ¹H NMR.

MS: [M−H]=378

2. Synthesis of Intermediate 61.2

5-[(4-ethylphenyl)isobutylsulfamoyl]-2-fluorobenzoic

A solution of 5-[(4-ethylphenyl)isobutylsulfamoyl]-2-fluorobenzoic acid (0.59 g; 1.55 mmol) in thionyl chloride (5.0 ml) is stirred for 3 hours at reflux and then concentrated to dryness. The 5-[(4-ethylphenyl)isobutylsulfamoyl]-2-fluorobenzoyl chloride (0.62 g; 100%) is obtained in the form of a brown oil.

MS: [M−H]=397

3. Synthesis of Intermediate 61.3

5-[(4-ethylphenyl)isobutylsulfamoyl]-2-fluorobenzamide

A 0.5M solution of ammonia in dioxane (8.4 ml; 4.2 mmol) is added portionwise over a period of 43 hours to a solution of 5-[(4-ethylphenyl)isobutylsulfamoyl]-2-fluorobenzoyl chloride (0.31 g; 0.78 mmol) in tetrahydrofuran (3 ml). The reaction medium is hydrolyzed with aqueous NaHCO₃ solution and extracted with ethyl acetate.

The extracted organic phase is washed with 1N sodium hydroxide, dried (Na₂SO₄), filtered and concentrated. The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 20 to 50% of ethyl acetate). The 5-[(4-ethylphenyl)isobutylsulfamoyl]-2-fluorobenzamide (0.17 g; 58%) is obtained in the form of a white solid with a compliant ¹H NMR.

MS: [M−H]=379

4. Synthesis of Intermediate 61.4

3-cyano-N-(4-ethylphenyl)-4-fluoro-N-isobutylbenzenesulfonamide

Triethylamine (0.19 ml; 1.35 mmol) and then trifluoroacetic anhydride (93 μl; 0.67 mmol) are added to a solution of 5-[(4-ethylphenyl)isobutylsulfamoyl]-2-fluorobenzamide (0.17 g; 0.45 mmol) at 0° C. The reaction medium is stirred for 1 hour, hydrolyzed for 15 minutes and extracted with ethyl acetate. The organic phases are combined, dried (Na₂SO₄), filtered and concentrated.

The 3-cyano-N-(4-ethylphenyl)-4-fluoro-N-isobutylbenzenesulfonamide (0.17 g; 89%) is obtained in the form of a white solid (HPLC purity=85%) with a compliant ¹H NMR.

MS: [M−H]=361

5. Synthesis of Compound 34 According to the Invention

Hydrazine hydrate (1.25 ml; 25.7 mmol) is added to a suspension of 3-cyano-N-(4-ethylphenyl)-4-fluoro-N-isobutylbenzenesulfonamide (0.19 g; 0.45 mmol) in ethanol (2.5 ml). The reaction medium is stirred for 50 minutes at a temperature of 100° C. in a tube. The reaction medium is concentrated.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.2% of ammonium carbonate). The 3-amino-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (78 mg; 53%) is obtained in the form of a solid.

¹H NMR (DMSO-d6) δ: 0.85 (d, J=6.6 Hz, 6H), 1.17 (t, J=7.5 Hz, 3H), 1.34-1.48 (m, 1H), 2.59 (q, J=7.7 Hz, 2H), 3.28-3.32 (m, 2H), 5.73 (s, 2H), 6.96 (d, J=7.8 Hz, 2H), 7.16 (d, J=7.8 Hz, 2H), 7.26 (d, J=8.8 Hz, 1H), 7.32 (d, J=8.8 Hz, 1H), 8.19 (s, 1H), 11.91 (s, 1H).

MS: [M−H]=373

Example 63: Synthesis of 3-amino-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide

3-Amino-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (54 mg; 0.14 mmol) in dimethyl sulfoxide (0.80 ml) is added to potassium hydroxide (29 mg; 0.44 mmol) at 85% in dimethyl sulfoxide (0.20 ml). The reaction medium is stirred for 5 minutes and 4-(bromomethyl)tetrahydropyran (27 mg; 0.15 mmol) in dimethyl sulfoxide (0.50 ml) is then added. Stirring is continued for 3 hours 20 minutes, followed by hydrolysis with a few drops of water and filtration through a filter syringe. The filtrate is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid).

The 3-amino-1-(tetrahydropyran-4-ylmethyl)-1H-indazole-5-sulfonic acid (4-ethylphenyl)isobutylamide (30 mg; 44%) is obtained in the form of a colorless oil.

¹H NMR (DMSO-d6) δ: 0.85 (d, J=6.6 Hz, 6H), 1.17 (t, J=7.6 Hz, 3H), 1.21-1.47 (m, 5H), 2.59 (q, J=7.6 Hz, 2H), 3.23 (td, J=11.5, 2.4 Hz, 2H), 3.77-3.88 (m, 2H), 4.03 (d, J=7.0 Hz, 2H), 6.92-7.01 (m, 2H), 7.16 (d, J=8.3 Hz, 2H), 7.26 (dd, J=8.9, 1.8 Hz, 1H), 7.51 (d, J=8.9 Hz, 1H), 8.17 (d, J=1.7 Hz, 1H).

MS: [M−H]=471

Part VI: Synthesis of the Bicyclic Sulfonamides Via Reaction Scheme 6

Example 64: Synthesis of 3-(tetrahydropyran-4-ylidenemethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

1. Synthesis of Intermediate 63.1

1H-Indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

A mixture of 1H-indazole-6-sulfonyl chloride (500 mg; 2.31 mmol), pyridine (3 ml) and (4-ethylphenyl)oxetan-3-ylmethylamine (491 mg; 2.77 mmol) is stirred for 30 minutes at a temperature of 50° C. The reaction medium is diluted with ethyl acetate.

The organic phase is washed with saturated NH₄Cl solution, with saturated NaHCO₃ solution and with water. It is dried over magnesium sulfate, filtered and concentrated to dryness.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 40% of ethyl acetate). The 1H-Indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (640 mg; 78%) is obtained in the form of a colorless oil and is obtained with a compliant ¹H NMR.

MS: [M+H]=358

2. Synthesis of Intermediate 63.2

3-bromo-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

N-Bromosuccinimide (956 mg; 5.37 mmol) is added to a solution of 1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (1.60 g; 4.48 mmol) in dichloromethane (10 ml). The reaction medium is stirred for 16 hours at room temperature and diluted with dichloromethane.

The organic phase is extracted and washed with saturated ammonium chloride solution, with saturated sodium hydrogen carbonate solution and with water. It is dried (MgSO₄), filtered and concentrated to dryness. The 3-bromo-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (1.9 g; 97%) is obtained in the form of a pale yellow solid with a compliant ¹H NMR.

MS: [M+H]=436

3. Synthesis of Intermediate 63.3

3-bromo-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

A mixture of 3-bromo-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (700 mg; 1.60 mmol), pyridinium p-toluenesulfonate (202 mg; 0.80 mmol) and 3,4-dihydro-2H-pyran (0.58 ml; 6.42 mmol) in tetrahydrofuran (10 ml) is stirred for 16 hours at 80° C. The reaction medium is diluted with ethyl acetate (20 ml) and extracted.

The organic phase is washed with saturated NH₄Cl solution, with saturated NaHCO₃ solution and with water, dried (MgSO₄), filtered and concentrated to dryness.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 3-bromo-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (500 mg; 57%) is obtained in the form of a white solid.

¹H NMR (DMSO-d6) δ: 0.86 (dd, J=13.3, 6.7 Hz, 6H), 1.18 (t, J=7.6 Hz, 3H), 1.38-1.63 (m, 3H), 1.68-1.81 (m, 1H), 1.98 (d, J=10.7 Hz, 2H), 2.60 (q, J=7.6 Hz, 2H), 3.36-3.41 (m, 2H), 3.67-3.76 (m, 1H), 6.00 (dd, J=9.3, 2.4 Hz, 1H), 6.95-7.02 (m, 2H), 7.16-7.21 (m, 2H), 7.41 (dd, J=8.5, 1.4 Hz, 1H), 7.83 (d, J=8.8 Hz, 1H), 7.99 (s, 1H)

MS: [M+H]=520

4. Synthesis of Intermediate 63.4

1-(tetrahydropyran-2-yl)-3-(tetrahydropyran-4-ylidenemethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

A mixture of p-toluenesulfonyl hydrazide (286 mg; 1.54 mmol), 4-formyltetrahydropyran (175 mg; 1.54 mmol) and 1,4-dioxane (2 ml) is stirred for 1 hour under argon. Lithium tert-butoxide (125 mg; 1.54 mmol), X-PHOS (18 mg; 0.04 mmol), tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (40 mg; 0.04 mmol) and 3-bromo-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (200 mg; 0.38 mmol) are added under argon, and the reaction medium is stirred for 5 hours at 100° C.

The reaction medium is diluted with 20 ml of ethyl acetate and extracted. The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄), filtered and concentrated.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 100% of ethyl acetate).

The 1-(tetrahydropyran-2-yl)-3-(tetrahydropyran-4-ylidenemethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (100 mg; 48%) is obtained in the form of a yellow oil with a compliant ¹H NMR.

MS: [M+H]=538

5. Synthesis of Compound 62 According to the Invention

A mixture of 1-(tetrahydropyran-2-yl)-3-(tetrahydropyran-4-ylidenemethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (100 mg; 0.19 mmol), acetic acid (6 ml) and water (2 ml) is stirred for 5 hours at a temperature of 80° C. The reaction medium is diluted with 20 ml of ethyl acetate and extracted. The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄), filtered and concentrated.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 100% of ethyl acetate). The 3-(tetrahydropyran-4-ylidenemethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (80 mg; 93%) is obtained in the form of a white solid.

¹H NMR (DMSO-d6) δ: 0.85 (d, J=6.7 Hz, 7H), 1.17 (t, J=7.6 Hz, 3H), 1.41 (dt, J=13.6, 6.8 Hz, 1H), 2.60 (q, J=7.3 Hz, 2H), 2.93 (t, J=5.4 Hz, 2H), 3.65 (t, J=5.5 Hz, 2H), 3.73 (t, J=5.4 Hz, 2H), 6.61 (s, 1H), 6.95 (d, J=8.3 Hz, 2H), 7.13-7.21 (m, 2H), 7.22 (dd, J=8.5, 1.5 Hz, 1H), 7.63-7.67 (m, 1H), 7.98 (d, J=8.5 Hz, 1H).

MS: [M+H]=454

Example 65: Synthesis of 3-(tetrahydropyran-4-ylmethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

3-(Tetrahydropyran-4-ylidenemethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (60 mg; 0.13 mmol) in methanol (3 ml) in the presence of palladium (5% Pd on activated charcoal: Degussa type) (14 mg) is placed for 16 hours under hydrogen (1 atm). The reaction medium is filtered through Celite. The filtrate is concentrated to dryness. The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 100% of ethyl acetate). The 3-(tetrahydropyran-4-ylmethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (30 mg; 50%) is obtained in the form of a white solid.

¹H NMR (DMSO-d6) δ: 0.85 (d, J=6.4 Hz, 6H), 1.17 (t, J=7.6 Hz, 3H), 1.23-1.48 (m, 3H), 1.56 (d, J=13.4 Hz, 2H), 1.97 (d, J=11.7 Hz, 1H), 2.56-2.65 (m, 2H), 2.90 (d, J=7.0 Hz, 2H), 3.26 (t, J=11.3 Hz, 2H), 3.82 (dd, J=11.6, 3.8 Hz, 2H), 6.97 (d, J=8.1 Hz, 2H), 7.19 (dd, J=14.2, 8.2 Hz, 3H), 7.62 (s, 1H), 7.95 (d, J=8.3 Hz, 1H), 13.15 (s, 1H).

MS: [M+H]=456

Part VII: Synthesis of the Bicyclic Sulfonamides Via Reaction Scheme 7

Example 65: Synthesis of 3-morpholin-4-ylmethyl-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

1. Synthesis of Intermediate 65.1

1-(tetrahydropyran-2-yl)-3-vinyl-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

Bis(tri-t-butylphosphine)palladium(0) (49 mg; 0.10 mmol) is added to a mixture, degassed under argon, of 3-bromo-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (500 mg; 0.96 mmol), cesium carbonate (940 mg; 2.88 mmol) and vinylboronic anhydride-pyridine complex (462 mg; 1.92 mmol) in 1,4-dioxane (3 ml) and water (1 ml).

The reaction medium is stirred for 3 hours at a temperature of 90° C. and filtered through Celite. The filtrate is diluted with ethyl acetate and extracted.

The organic phase is washed with 20 ml of saturated sodium hydrogen carbonate solution and with 20 ml of water. The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄), filtered and concentrated.

The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 100% of ethyl acetate). The 1-(tetrahydropyran-2-yl)-3-vinyl-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (400 mg; 89%) is obtained in the form of a beige-colored solid with a compliant ¹H NMR.

MS: [M+H]=468

2. Synthesis of Intermediate 65.2

3-(1,2-dihydroxyethyl)-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

1-(Tetrahydropyran-2-yl)-3-vinyl-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (400 mg; 0.86 mmol) is added to a mixture of (DHQ)₂PHAL (1.20 g; 1.46 mmol), tert-butyl alcohol (10 ml) and water (10 ml) cooled to a temperature of 0° C. The reaction medium is stirred for 16 hours at a temperature of 40° C. Sodium sulfite (5 g) is added.

The reaction medium is stirred for 45 minutes, diluted with ethyl acetate (30 ml) and extracted. The organic phases are combined, washed with saturated Na₂SO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄), filtered and concentrated. The crude product is chromatographed on silica gel (eluent: heptane/ethyl acetate, from 0 to 100% of ethyl acetate).

The 3-(1,2-dihydroxyethyl)-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (380 mg; 89%) is obtained in the form of a clear oil with a compliant ¹H NMR.

MS: [M+H]=502

3. Synthesis of Intermediate 65.3

3-formyl-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

Sodium metaperiodate (1.62 g; 7.58 mmol) is added to a mixture of 3-(1,2-dihydroxyethyl)-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (380 mg; 0.76 mmol), acetone (2 ml), tetrahydrofuran (2 ml) and water (2 ml).

The reaction medium is stirred for 2 hours 30 minutes at a temperature of 35° C., diluted with ethyl acetate (30 ml) and water (20 ml) and extracted.

The organic phases are combined, washed with saturated Na₂SO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄), filtered and concentrated. The 3-formyl-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (120 mg; 34%) is obtained in the form of a white solid with a compliant ¹H NMR.

MS: [M+H]=470

4. Synthesis of Intermediate 65.4

3-morpholin-4-ylmethyl-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

Morpholine (45 μl; 0.51 mmol) and sodium triacetoxyborohydride (119 mg; 0.56 mmol) are added to a solution of 3-formyl-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (120 mg; 0.26 mmol) in tetrahydrofuran (3 ml). The reaction medium is stirred for 2 hours at room temperature. The reaction medium is diluted with ethyl acetate (20 ml) and water (10 ml) and extracted.

The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄) and concentrated.

The 3-morpholin-4-ylmethyl-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (130 mg; 94%) is obtained in the form of an oil with a compliant ¹H NMR.

MS: [M+H]=541

5. Synthesis of Compound 64 According to the Invention

A mixture of 3-morpholin-4-ylmethyl-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (130 mg; 0.24 mmol), acetic acid (30 ml) and water (10 ml) and a few drops of trifluoroacetic acid is stirred for 4 days at a temperature of 80° C. The reaction medium is diluted with 50 ml of ethyl acetate and extracted.

The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄), filtered and concentrated.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 3-morpholin-4-ylmethyl-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (70 mg; 64%) is obtained in the form of a white solid after recrystallization from an acetone/water mixture.

1H NMR (DMSO-d6) δ: 0.85 (d, J=6.7 Hz, 6H), 1.18 (t, J=7.6 Hz, 3H), 2.44 (t, J=4.5 Hz, 4H), 2.61 (t, J=7.6 Hz, 2H), 3.33-3.37 (m, 2H), 3.87 (s, 2H), 6.95-7.00 (m, 2H), 7.15-7.21 (m, 2H), 7.25 (dd, J=8.5, 1.5 Hz, 1H), 8.06 (d, J=8.5 Hz, 1H), 13.27 (s, 1H).

MS: [M+H]=457

Example 66: Synthesis of 3-((cis)-2,6-dimethylmorpholin-4-ylmethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

1. Synthesis of Intermediate 66.1

3-((2S,6R)-2,6-dimethylmorpholin-4-ylmethyl)-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

cis-2,6-Dimethylmorpholine (50 μl; 0.38 mmol) and sodium triacetoxyborohydride (122 mg; 0.57 mmol) are added to a solution of 3-formyl-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (90 mg; 0.19 mmol) in tetrahydrofuran (2 ml).

The reaction medium is stirred for 16 hours at room temperature. The reaction medium is diluted with ethyl acetate (20 ml) and water (10 ml) and extracted. The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄) and concentrated. The 3-((2S,6R)-2,6-dimethylmorpholin-4-ylmethyl)-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (90 mg; 83%) is obtained in the form of an oil with a compliant ¹H NMR.

MS: [M+H]=570

2. Synthesis of Compound 65 According to the Invention

A mixture of 3-((2S,6R)-2,6-dimethylmorpholin-4-ylmethyl)-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (90 mg; 0.16 mmol), acetic acid (10 ml) and water (10 ml) and one drop of trifluoroacetic acid is stirred for 16 hours at a temperature of 80° C. The reaction medium is diluted with 50 ml of ethyl acetate and extracted.

The organic phase is washed with saturated NH₄Cl solution (20 ml), with saturated NaHCO₃ solution (20 ml) and with water (20 ml), dried (MgSO₄), filtered and concentrated.

The crude product is purified by preparative HPLC (C18 column, eluent: acetonitrile in water/0.1% of formic acid). The 3-((cis)-2,6-dimethylmorpholin-4-ylmethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (52 mg; 67%) is obtained in the form of a colorless oil.

1H NMR (DMSO-d6) δ: 0.85 (d, J=6.5 Hz, 6H), 1.02 (d, J=6.1 Hz, 6H), 1.18 (t, J=7.5 Hz, 3H), 1.42 (dt, J=13.3, 7.1 Hz, 1H), 1.74 (t, J=10.7 Hz, 2H), 2.55-2.65 (m, 2H), 2.70-2.80 (m, 2H), 3.33-3.44 (m, 2H), 3.55 (t, J=7.8 Hz, 2H), 3.85 (s, 2H), 6.98 (d, J=8.0 Hz, 2H), 7.17 (d, J=8.3 Hz, 2H), 7.23 (d, J=8.6 Hz, 1H), 7.66 (s, 1H), 8.03 (d, J=8.6 Hz, 1H), 8.20 (s, 1H), 13.25 (s, 1H).

MS: [M+H]=485

Example 67: Synthesis of 3-((S)-3-methylmorpholin-4-ylmethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

1. Synthesis of Intermediate 67.1

3-((S)-3-methylmorpholin-4-ylmethyl)-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide

With a procedure similar to that described for intermediate 67.1, 3-((S)-3-methylmorpholin-4-ylmethyl)-1-(tetrahydropyran-2-yl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (90 mg; 85%) is obtained in the form of an oil with a compliant ¹H NMR.

MS: [M+H]=555

2. Synthesis of Compound 66 According to the Invention

With a procedure similar to that described for example 66, 3-((S)-3-methylmorpholin-4-ylmethyl)-1H-indazole-6-sulfonic acid (4-ethylphenyl)isobutylamide (42 mg; 54%) is obtained in the form of a colorless oil.

1H NMR (DMSO-d6) δ: 0.86 (d, J=6.8 Hz, 6H), 1.09-1.22 (m, 7H), 1.42 (dt, J=13.9, 6.9 Hz, 1H), 2.16-2.27 (m, 1H), 2.61 (t, J=7.6 Hz, 2H), 3.38 (d, J=19.0 Hz, 5H), 3.58-3.72 (m, 3H), 6.98 (d, J=7.9 Hz, 2H), 7.18 (d, J=7.9 Hz, 2H), 7.26 (d, J=8.5 Hz, 1H), 7.65 (s, 1H), 8.04 (d, J=8.6 Hz, 1H), 8.24 (s, 1H), 13.24 (s, 1H).

MS: [M+H]=471 

1. A compound of formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof and/or a solvate thereof:

wherein: L represents a single bond or a methylene group CH₂, X represents a cyclic radical chosen from the radicals X₁ and X₂ below:

one or two of the elements Y¹, Y², Y³, Y⁴ and Y⁵ represent(s) a nitrogen atom and the other elements correspond to a group —CR², or each of the elements Y¹-, Y², Y³, Y⁴ and Y⁵ corresponds to a group —CR², each of the elements Q¹, Q² and Q³ corresponds to an identical or different —CR^(2a) group, R¹ represents a linear or branched C₃-C₅ alkyl radical, optionally substituted with a hydroxyl group and/or a halogen atom, a C₃-C₅ cycloalkyl radical, a linear or branched C₂-C₅ alkenyl radical, a —CH₂—(C₃-C5)cycloalkyl radical, a C₄-C₅ heterocycloalkyl radical, a —CH₂—(C₄-C₆)heterocycloalkyl radical, R² represents a hydrogen atom or a halogen atom, a linear or branched C₁-C₅ alkyl radical, a linear or branched C₂-C₄ alkenyl radical, a C₁-C₄ alkoxy radical, a cyano group —CN, a radical —C(═O)R′² with R′² denoting a C₁-C₃ alkoxy radical, a —CF₃ radical; said alkyl, alkenyl and alkoxy radicals optionally being substituted with one or more halogen atoms, R^(2a) represents a hydrogen atom or a halogen atom, a linear or branched C₁-C₅ alkyl radical, a linear or branched C₂-C₄ alkenyl radical, a C₁-C₄ alkoxy radical, a-CN group, a hydroxyl group —OH, a group —CH(R^(3a))_(o)H, a carboxylic group —COOH, a carbamoyl group —CONR^(2c)R^(2d), an amido group —NR^(2c)COR^(2d), a group —SO₂R^(2c), a group —SOR^(2c), a group —S(═O)(═NH—R^(2c)), said alkyl, alkenyl and alkoxy radicals optionally being substituted with one or more halogen atoms, R^(2c) and R^(2d), which are identical or different, represent a hydrogen atom or a linear or branched C₁-C₅ alkyl radical; R^(3a) represents a hydrogen atom or a linear or branched C₁-C₅ alkyl radical, R³ represents a hydrogen atom, a halogen atom, a group (CHR⁶)_(n)—(Z)_(o)—(CHR^(′6))_(p)—R⁷ or a group CH═R⁷, n, o and p, which are identical or different, represent zero or a natural integer ranging from 1 to 3, Z represents a divalent group selected from the group consisting of a methylene group —CH₂—, an amino group —NH— and an oxygen atom —O—, R⁶ and R^(′6), which are identical or different, represent a hydrogen atom, a methyl group —CH₃, a group —OH, a hydroxymethyl group, or a carboxylic function-COOH, R⁷ represents: a hydrogen or a halogen atom, a group COOR^(′7) with R^(′7) denoting (C₁)alkyl(C₆)heterocycle, a heterocycloalkyl radical, wherein the heterocycloalkyl radical is optionally substituted with one or more halogen atoms, one or more linear or branched C₁-C₃ alkyl groups, one or more —OH groups, one or more carbonyl functions, one or more linear or branched C₁-C₄ hydroxyalkyl groups, one or more amino groups, one or more groups —C(═O)R^(7a), one or more groups S(═O)₂R^(7a); R^(7a) representing a linear or branched C₁-C₃ alkyl radical, a linear or branched C₁-C₃ alkoxy radical, or an amino radical N(R^(8a))(R^(8b)), a C₃-C₆ cycloalkyl radical, wherein the cycloalkyl radical is optionally substituted with one or more methyl radicals, one or more halogen atoms, a cyano group —CN or one or more groups —COR¹³; R¹³ denoting a linear or branched C₁-C₃ alkoxy radical, or a hydroxyl group, an aromatic radical, wherein the aromatic radical is optionally substituted with one or more halogen atoms, one or more linear or branched C₁-C₃ alkyl groups optionally substituted with one or more halogen atoms, one or more C₁-C₃ alkoxy groups, one or more amino groups —NR¹¹R¹², one or more groups —COR¹¹, one or more groups —COOR¹¹, one or more amido groups-CONR¹¹R¹², one or more groups —SOR¹¹, one or more groups —SO₂R¹¹, one or more groups —NHCOR¹¹, one or more groups —NHCOOR¹¹, one or more groups —SO₂NR¹¹R¹² or one or more —CN groups; R¹¹ and R¹², which are identical or different, representing a hydrogen atom, a hydroxyl radical —OH, a linear or branched C₁-C₃ alkyl radical optionally substituted with one or more halogen atoms; a heteroaromatic radical, wherein the heteroaromatic radical is optionally substituted with one or more halogen atoms, one or more linear or branched C₁-C₃ alkyl groups optionally substituted with one or more halogen atoms, one or more C₁-C₃ alkoxy groups, one or more amino groups —NR¹¹R¹², one or more groups —COR¹¹, one or more groups —COOR¹¹, one or more amido groups-CONR¹¹R¹², one or more groups —SOR¹¹, one or more groups —SO₂R¹¹, one or more groups —NHCOR¹¹, one or more groups —NHCOOR¹¹, one or more groups —SO₂NR¹¹R¹² or one or more —CN groups; R¹¹ and R¹², which are identical or different, representing a hydrogen atom, a hydroxyl radical —OH, a linear or branched C₁-C₃ alkyl radical optionally substituted with one or more halogen atoms; R⁵ represents a hydrogen atom, a linear or branched C₁-C₃ alkyl radical optionally substituted with one or more halogen atoms; an amino radical —NH₂, a C₄-C₅ heterocyclic radical, an OCH₂—(C₄-C₅) heterocyclic radical, a radical CH₂R^(′7)a with R^(′7)a denoting a methoxy radical, a hydroxyl group —OH, a —CH₂COOH group, a group —CH(R^(5b))OH, a carboxylic group —COOH, a —CN group, a thioxo function, R^(5b) represents a hydrogen atom, a linear or branched C₁-C₃ alkyl radical optionally substituted with one or more carboxylic functions; a cyclopropyl radical, and R^(8a) and R^(8b), which are identical or different, denote a hydrogen atom, a linear or branched C₁-C₃ alkyl radical or a cyclopropyl radical.
 2. The compound of formula (I) as defined by claim 1, wherein R⁷ represents a heterocyclic radical selected from the group consisting of:

in which: R_(7a) represents a linear or branched C₁-C₃ alkyl radical, a linear or branched C₁-C₃ alkoxy radical or an amino radical N(R^(8a))(R^(8b)), R^(8a) and R^(8b), which may be identical or different, denote a hydrogen atom, a linear or branched C₁-C₃ alkyl radical or a cyclopropyl radical, R⁸ and R⁹, which are identical or different, represent a hydrogen atom, a linear or branched C₁-C₃ alkyl radical, a hydroxyl group —OH, a carbonyl function ═O, a C₁ hydroxyalkyl radical (—CH₂OH), an amino group NH₂, R⁸ and R⁹ can form, together with the carbon atoms to which they are attached, a 5- to 7-membered carbocyclic ring.
 3. The compound of formula (I) as defined by claim 1, wherein R⁷ represents an aromatic or heteroaromatic radical selected from the group consisting of:

in which: R₁₀ represents a hydrogen atom or a halogen atom, one linear or branched C₁-C₃ alkyl group optionally substituted with one or more halogen atoms, one C₁-C₃ alkoxy group, one amino group —NR¹¹R¹², one group —COR¹¹, one group —COOR¹¹, one amido group —CONR¹¹R¹², one group —SOR¹¹, one group —SO₂R¹¹, one group —NHCOR¹¹, one group —NHCOOR¹¹, one group —SO₂NR¹¹R¹² or one —CN group; R¹¹ and R¹², which are identical or different, representing a hydrogen atom or a linear or branched C₁-C₃ alkyl radical optionally substituted with one or more halogen atoms, m denotes zero or a natural integer ranging from 1 to
 3. 4. The compound of formula (I) as defined by claim 1, wherein the compound, the pharmaceutically acceptable salt thereof, the hydrate thereof and/or the solvate thereof, has a structure of formula (II):

wherein R¹, R³, R⁵ and Y¹ to Y⁵ have the same meanings as in formula (I).
 5. The compound of formula (I) as defined by claim 1, wherein the compound has the structure of formula (III), and also the pharmaceutically acceptable addition salts thereof, hydrates thereof and/or solvates thereof:

wherein R¹, R³, R⁵ and Y¹ to Y⁵ have the same meanings as in formula (I).
 6. The compound of formula (I) as defined by claim 1, wherein the compound is selected from the group consisting of:


7. A pharmaceutical composition comprising at least one compound of formula (I) according to claim 1, a pharmaceutically acceptable salt thereof, a hydrate thereof and/or a solvate thereof.
 8. The pharmaceutical composition as defined by claim 7, wherein the composition is formulated for topical or oral administration.
 9. The pharmaceutical composition as defined by claim 7, wherein the composition is formulated for treating acne, atopic dermatitis and/or psoriasis.
 10. The pharmaceutical composition as defined by claim 8, wherein the composition is formulated for oral administration in the form of a table, a gel capsule, a coated tablet, a syrup, a suspension, a solution, a powder, a granule, an emulsion, a suspension comprising a microsphere, a suspension comprising a nanosphere, a lipid vesical, or a polymeric vesicle.
 11. The pharmaceutical composition as defined by claim 8, wherein the composition is formulated for topical administration in the form of an ointment, a cream, a milk, a pomade, a powder, an impregnated pad, a syndet, a solution, a gel, a spray, a mousse, a suspension, a stick, a shampoo, or a washing base. 